MORPHOGEN TREATMENT FOR CHRONIC RENAL FAILURE

Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family of the TGF- beta superfamily of proteins, or the administration of certain morphogens, inducers of those morphogens, agonists of the corresponding morphogen receptors, or implantation of renal cells induced with those morphogens. The morphogens useful in the invention are also members of, or based upon, the OP/BMP family of proteins.

Description: MORPHOGEN TREATMENT FOR CHRONIC RENAL FAILURE Field ofthe Invention The present invention relates generally to methods of treatment for renal disease. In particular, the invention relates to methods of treatment for conditions which place mammals, including humans, in, or at risk of, chronic renal failure. The methods preferably involve the administration of certain proteins ofthe osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins. More generally, the methods involve the administration of certain morphogens, inducers of those morphogens, or agonists ofthe corresponding morphogen receptors, or implantation of renal cells induced with those morphogens. Background ofthe Invention The mammalian renal system serves primary roles both in the removal of catabolic waste products from the bloodstream and in the maintenance of fluid and electrolyte balances in the body. Renal failures are, therefore, life-threatening conditions in which the build-up of catabolites and other toxins, and/or the development of significant imbalances in electrolytes or fluids, may lead to the failure of other major organs systems and death. As a general matter, renal failure is classified as "acute" or "chronic." As detailed below, the differences between these two conditions are not merely a matter of severity or rapidity but, rather, reflect differences in etiology, prognosis, and treatment. Acute Renal Failure Acute renal failure is defined as an abrupt cessation or substantial reduction of renal function and, in as many as 90-95% of cases, may be secondary to trauma, surgery or another acute medical condition. Acute renal failure may be due to pre-renal causes (e.g., decreased cardiac output, hypovolemia, altered vascular resistance) or to post-renal causes (e.g., obstructions or constrictions ofthe ureters, bladder or urethra) which do not directly involve the kidneys and which, if treated quickly, will not entail significant loss of nephrons or other damage to the kidneys. Alternatively, acute renal failure may be due to intrinsic renal causes which involve a more direct insult or injury to the kidneys, and which may entail permanent damage to the nephrons or other kidney structures. Intrinsic causes of acute renal failure include but are not limited to infectious diseases (e.g., various bacterial, viral or parasitic infections), inflammatory diseases (e.g., glomerulonephritis, systemic lupus erythematosus), ischemia (e.g., renal artery occlusion), toxic syndromes (e.g., heavy metal poisoning, side-effects of antimicrobial treatments or chemotherapy), and direct traumas. The diagnosis and treatment of acute renal failure is as varied as its causes. In human patients, oliguria (urine output < 400 ml/day) or anuria (urine output < 50 ml/day) may be present in 50-70% of cases, BUN levels may climb 10-20 mg/dL/day or faster, plasma creatinine levels may climb 0.5-1.0 mg/dL/day, and metabolic acidosis is almost always present. If not treated, the electrolyte and fluid imbalances (e.g., hyperkalemia, acidosis, edema) associated with acute renal failure may lead to life-threatening airhythmia, congestive heart failure, or multiple organ system failures. Present therapies are typically directed at the underlying causes ofthe acute renal failure (e.g., pre-renal, post-renal, or infectious causes) and management ofthe complications. Due to the severity of acute renal failure, episodes rarely last longer than several weeks without mortality and are treated on an in-patient basis. Chronic Renal Failure Chronic renal failure may be defined as a progressive, permanent and significant reduction ofthe glomerular filtration rate (GFR) due to a significant and continuing loss of nephrons. Chronic renal failure typically begins from a point at which a chronic renal insufficiency (i.e., a permanent decrease in renal function of at least 50-60%) has resulted from some insult to the renal tissues which has caused a significant loss of nephron units. The initial insult may or may not have been associated with an episode of acute renal failure. Irrespective ofthe nature ofthe initial insult, chronic renal failure manifests a "final common path" of signs and symptoms as nephrons are progressively lost and GFR progressively declines. This progressive deterioration in renal function is slow, typically spanning many years or decades in human patients, but seemingly inevitable. The early stage of chronic renal failure typically begins when GFR has been reduced to approximately one-third of normal (e.g., 30-40 ml/min for an average human adult). As a result ofthe significant nephron loss, and in an apparent "attempt" to maintain the overall GFR with fewer nephrons, the average single nephron GFR (SNGFR) is increased by adaptations ofthe remaining nephrons at both the structural and functional level. One structural manifestation of this adaptation, readily detectable by microscopic examination of biopsy samples, is a " compensatory hypertrophy" of both the glomeruli and the tubules ofthe kidney, a process which literally increases the volume of filtrate which can be produced by each remaining nephron by literal enlargement ofthe glomeruli and tubules. Indeed, as a result ofthe hypertrophy or dilation ofthe collecting ducts, the urine of subjects with chronic renal failure often contains broad "casts," typically 2-6 times normal diameter, which aid in diagnosis and have also been referred to as "renal failure casts." At the same time, there are functional changes in the remaining nephrons, such as decreased absoφtion or increased secretion of normally excreted solutes, which may be responses to hormonal or paracrine changes elsewhere in the body (e.g., increasing levels of parathyroid hormone (PTH) in response to changes in serum levels of calcium and phosphate). These adaptations in early stage chronic renal failure are not successful in completely restoring GFR or other parameters of renal function and, in fact, subject the remaining nephrons to increased risk of loss. For example, the increased SNGFR is associated with mechanical stresses on the glomerulus due to hypertension and hyperperfusion. The loss of integrity of podocyte junctures leads to increased permeability ofthe glomerulus to macromolecules or "leakiness" ofthe glomerular capsule. Proliferative effects are also observed in mesangial, epithelial and endothelial cells, as well as increases in the deposition of collagen and other matrix proteins. Sclerosis of both the glomeruli and tubules is another common symptom ofthe hypertrophied nephrons and the risk of coagulation in the glomerulus is increased. In particular, these adaptations ofthe remaining nephrons, by pushing the SNGFR well beyond its normal level, actually decrease the capacity ofthe remaining nephrons to respond to acute changes in water, solute, or acid loads and, therefore, actually increase the probability of additional nephron loss. As chronic renal failure progresses, and GFR continues to decline to less than 10% of normal (e.g., 5-10 ml/min), the subject enters end-stage renal disease (ESRD). During this phase, the inability ofthe remaining nephrons to adequately remove waste products from the blood, while retaining useful products and maintaining fluid and electrolyte balance, leads to a rapid decline in which many organ systems, and particularly the cardiovascular system, may begin to fail. For example, BUN and creatinine levels may be expected to rise and, at BUN levels of 60- 100 mg/dL and serum creatinine levels of 8-12 mg/dL, a uremic syndrome will typically develop in which the kidneys can no longer remove the end products of nitrogen metabolism. At this point, renal failure will rapidly progress to death unless the subject receives renal replacement therapy (i.e., chronic hemodialysis, continuous peritoneal dialysis, or kidney transplantation). Approximately 600 patients per million receive chronic dialysis each year in the United States, at an average cost approaching $60,000-$80,000 per patient per year. Ofthe new cases of end-stage renal disease each year, approximately 28-33% are due to diabetic nephropathy (or diabetic glomerulopathy or diabetic renal hypertrophy), 24-29% are due to hypertensive nephrosclerosis (or hypertensive glomerulosclerosis), and 15-22% are due to glomerulonephritis. The 5-year survival rate for all chronic dialysis patients is approximately 40%, but for patients over 65, the rate drops to approximately 20%. Morphogens and Growth Factors A great many proteins have now been identified which appear to act as morphogenetic or growth factors, regulating cell proliferation or differentiation. Typically these growth factors exert their effects on specific sets or subsets of cells or tissues. Thus, for example, epidermal growth factors, nerve growth factors, fibroblast growth factors, various hormones, and many other proteins inducing or inhibiting cell proliferation or differentiation have been identified and shown to affect some subgroup of cells or tissues. One group of morphogenetic proteins, referred to herein as "morphogens," includes members ofthe family of osteogenic proteins/bone morphogenetic proteins (OP/BMPs) which were initially identified by their ability to induce ectopic, endochondral bone morphogenesis. Subsequent characterization ofthe nucleic acid and amino acid sequences ofthe BMPs has shown them to be a subgroup ofthe TGF-β superfamily of growth factors. Members of this morphogen family have now been shown to include the mammalian osteogenic protein- 1 (OP-1, also known as BMP-7), osteogenic protein-2 (OP-2), osteogenic protein-3 (OP-3), BMP-2 (also known as BMP-2A or CBMP-2A), BMP-3, BMP-4 (also known as BMP-2B or CBMP-2B), BMP-5, BMP-6, Vgr-1, and GDF-1, as well as the Xenopus homologue Vgl and the Drosophila homologues DPP and 60 A. Members of this family encode secreted polypeptides that share common structural features and that are similarly processed from pro-proteins to yield carboxy terminal mature proteins having a conserved pattern of cysteines. The active forms of these proteins are either disulfide-bonded homodimers of a single family member, or heterodimers of two different members (see, e.g., Massague (1990) Annu. Rev. Cell Biol. 6:597; Sampath, et al. (1990) J. Biol. Chem. 265:13198). The members ofthe morphogen family of proteins are expressed in a variety of tissues during development. BMP-3 for, example, has been shown to be expressed in developing human lung and kidney (Vukicevic et al. (1994) J. Histochem. Cvtochem. 42:869-875), BMP-4 has been shown to be expressed in the developing limbs, heart, facial processes and condensed mesenchyme associated with early whisker follicles in embryonic mice (Jones, et al. (1991) Development 111 :531-542), and OP-1 (BMP-7) has been shown immunohistochemically to be associated with basement membranes in human embryos, including those ofthe developing lungs, pancreas, skin, and convoluted tubules of kidneys (Vukicevic, et al. (1994) Biochem. Biophys. Res. Commun. 198:693-700). Some ofthe moφhogens (e.g., OP-2 and BMP-2) were not detected in analyses of adult tissues, suggesting only an early developmental role for these morphogens (Ozkaynak, et al. (1992) J. Biol. Chem. 267:25220-25227). In contrast, high levels of murine OP-1 expression have been observed in adult mouse kidneys (Ozkaynak, et al. (1991) Biochem. Biophys. Res. Commun, 179:116-123). This suggests a possible role for OP-1 synthesized in the kidney as a paracrine regulator of bone growth, and would be consistent with the role ofthe kidneys in both calcium regulation and bone homeostasis. A great variety of growth factors have been considered which may participate in the regulation ofthe growth and repair of renal tissues (reviewed in, e.g., Toback (1992) Kidney Intl. 41 :226-246). For example, EGF, TGF-α, TGF-β, IGF-I, IGF-II, PDGF, FGF, Renin/Angiotensin II, IL-1 and OP-1 have all been found to be expressed by various adult renal cells or tissues and to have effects on renal cell proliferation or differentiation (see, Toback (1992) supra. Ozkaynak, et al. (1991) supra). In addition, several of these have been found to be expressed in the developing kidney, including IGF-I, TGF-β and OP-1 (reviewed in, e.g., Bard, et al. (1994) Mech. Develop. 48:3-1 1). Interestingly, TGF-β has been shown in a murine metanephric organ culture system to retard overall growth and segmental differentiation of all segments of developing nephrons except the thick ascending limb-early distal tubules (Avner and Sweeney (1990) Pediatr. Nephrol. 4:372- 377). In addition, TGF-β expression has been found to be increased in several models of renal disease, suggesting that TGF-β mediated increases in the synthesis of extracellular matrix components may be involved in the etiology of diabetic nephropathy (or diabetic glomerulopathy or diabetic renal hypertrophy), renal fibrosis, glomerulosclerosis and glomerulonephritis, interstitial fibrosis, and hypertensive nephrosclerosis (Shankland, et al. (1994) Kidney Intl. 46:430-442; Yamamoto, et al. (1994) Kidnev Intl. 45:916-927; Yamamoto, et al. (1993) PNAS 90: 1814-1818; Tamaki, et al. (1994) Kidnev Intl. 45:525-536: Border, et al. (1990) Nature 346:371-374; Hamaguchi, et al. (1995) Hypertension 26:199-207). Also of interest is the fact that serum levels of human growth hormone (GH) are elevated in subjects with chronic renal failure (Wright et al. (1968) Lancet 2:798; Samaan and Freeman (1970) Metabolism 19: 102). Recombinant GH has been shown to help maintain protein balance in malnourished chronic renal failure patients, and to promote "catch-up" growth in children with chronic renal failure. It has been suggested that these effects are mediated by IGF-I (see, e.g., Kopple (1992) Miner. Electrolyte Metab. 18:269-275). Although some studies have found that the administration of IGF-I increases renal plasma flow and GFR in chronic renal failure patients (e.g., Guler, et al. (1989) PNAS 86:2868-2872: Hirschberg, et al. (1993) Kidnev Intl. 43:387- 397), other studies have found that this effect is merely transient (Miller, et al. (1994) Kidney Intl. 46:201-207). Thus, although some growth factors have been shown to be expressed in both developing and adult renal tissues, and although at least one has been shown to increase renal function in the short term, none has yet been shown to be of therapeutic benefit in preventing, inhibiting, or delaying the progressive loss of renal function that characterizes chronic renal failure. A need remains, therefore, for treatments which will prevent the progressive loss of renal function which causes hundreds of thousand of patients to become dependent upon chronic dialysis, and which results in the premature deaths of tens of thousands each year. Summary ofthe Invention The present invention is directed to methods of treatment, and pharmaceutical preparations for use in the treatment, of mammalian subjects in, or at risk of, chronic renal failure, or at risk ofthe need for renal replacement therapy. Such subjects include subjects already afflicted with chronic renal failure, or which have already received renal replacement therapy, as well as any subject reasonably expected to suffer a progressive loss of renal function associated with progressive loss of functioning nephron units. Whether a particular subject is at risk is a determination which may routinely be made by one of ordinary skill in the relevant medical or veterinary art. Subjects in, or at risk of, chronic renal failure, or at risk ofthe need for renal replacement therapy, include but are not limited to the following: subjects which may be regarded as afflicted with chronic renal failure, end-stage renal disease, chronic diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, hereditary nephritis, and/or renal dysplasia; subjects having a biopsy indicating glomerular hypertrophy, tubular hypertrophy, chronic glomerulosclerosis, and/or chronic tubulointerstitial sclerosis; subjects having an ultrasound, MRI, CAT scan, or other non-invasive examination indicating renal fibrosis; subjects having an unusual number of broad casts present in urinary sediment; subjects having a GFR which is chronically less than about 50%, and more particularly less than about 40%, 30% or 20%, ofthe expected GFR for the subject; human male subjects weighing at least about 50 kg and having a GFR which is chronically less than about 50 ml/rnin, and more particularly less than about 40 ml/min, 30 ml/min or 20 ml/min; human female subjects weighing at least about 40 kg and having a GFR which is chronically less than about 40 ml/min, and more particularly less than about 30 ml/min, 20 ml/min or 10 ml/min; subjects possessing a number of functional nephron units which is less than about 50%, and more particularly less than about 40%, 30% or 20%, of the number of functional nephron units possessed by a healthy but otherwise similar subject; subjects which have a single kidney; and subjects which are kidney transplant recipients. The methods and compositions of this invention capitalize in part upon the discovery that certain proteins of eukaryotic origin may be used as renal therapeutic agents in the treatment of subjects at risk, as defined herein, of chronic renal failure or the need for renal replacement therapy. Generally, these renal therapeutic agents are proteins, or are based upon proteins, which are members ofthe osteogenic protein/bone morphogenetic protein (OP/BMP) family of proteins. Thus, useful OP/BMP renal therapeutic agents ofthe invention include polypeptides, or functional variants of polypeptides, comprising at least the C-terminal six- or seven-cysteine domain of a mammalian protein selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, and proteins which exhibit at least 70% or, more preferably, 75% or 80% amino acid sequence homology with the amino acid sequence ofthe seven-cysteine domain of human OP-1; and which are (a) capable of inducing chondrogenesis in the Reddi- Sampath ectopic bone assay (Sampath and Reddi (1981), Proc. Natl. Acad. Sci. (USA) 78:7599- 7603) or a substantially equivalent assay, (b) capable of significantly preventing, inhibiting, delaying or alleviating the progressive loss of renal function in a standard animal model of chronic renal failure, or (c) capable of causing a clinically significant improvement in a standard marker of renal function when administered to a mammal in, or at risk of, chronic renal failure. More generally speaking, the invention provides for the use of "morphogens" which are dimeric proteins that induce morphogenesis of one or more eukaryotic (e.g., mammalian) cells, tissues or organs. Of particular interest herein are morphogens that induce morphogenesis at least of mammalian renal tissue, including formation of functional renal epithelium and, in particular, functional glomerular and tubular epithelium. Morphogens comprise a pair of polypeptides that, when folded, adopt a configuration sufficient for the resulting dimeric protein to elicit morphogenetic responses in cells and tissues displaying receptors specific for said morphogen. That is, morphogens generally induce all ofthe following biological functions in a moφhogenically permissive environment: stimulating proliferation of progenitor cells; stimulating the differentiation of progenitor cells; stimulating the proliferation of differentiated cells; and supporting the growth and maintenance of differentiated cells. "Progenitor" cells are uncommitted cells that are competent to differentiate into one or more specific types of differentiated cells, depending on their genomic repertoire and the tissue specificity ofthe permissive environment in which morphogenesis is induced. Moφhogens further can delay or mitigate the onset of senescence- or quiescence-associated loss of phenotype and/or tissue function. Morphogens still further can stimulate phenotypic expression of differentiated cells, including expression of metabolic and/or functional, e.g., secretory, properties thereof. In addition, moφhogens can induce redifferentiation of committed cells under appropriate environmental conditions. As noted above, morphogens that induce proliferation and/or differentiation at least of mammalian renal tissue, and/or support the growth, maintenance and/or functional properties of mammalian nephrons, are of particular interest herein. In preferred embodiments, the pair of morphogen polypeptides have amino acid sequences each comprising a sequence that shares a defined relationship with an amino acid sequence of a reference morphogen. Herein, preferred morphogen polypeptides share a defined relationship with a sequence present in morphogenically active human OP-1, SEQ ID NO: 4. However, any one or more ofthe naturally occurring or biosynthetic sequences disclosed herein similarly could be used as a reference sequence. Preferred morphogen polypeptides share a defined relationship with at least the C-terminal six cysteine domain of human OP-1, residues 43-139 of SEQ ID NO: 4. Preferably, moφhogen polypeptides share a defined relationship with at least the C- terminal seven cysteine domain of human OP-1, residues 38-139 of SEQ ID NO: 4. That is, preferred morphogen polypeptides in a dimeric protein with morphogenic activity each comprise a sequence that corresponds to a reference sequence or is functionally equivalent thereto. Functionally equivalent sequences include functionally equivalent arrangements of cysteine residues disposed within the reference sequence, including amino acid insertions or deletions which alter the linear arrangement of these cysteines, but do not materially impair their relationship in the folded structure ofthe dimeric morphogen protein, including their ability to form such intra- or inter-chain disulfide bonds as may be necessary for morphogenic activity. Functionally equivalent sequences further include those wherein one or more amino acid residues differs from the corresponding residue of a reference morphogen sequence, e.g., the C-terminal seven cysteine domain (or "skeleton") of human OP-1, provided that this difference does not destroy moφhogenic activity. Accordingly, conservative substitutions of corresponding amino acids in the reference sequence are preferred. Amino acid residues that are "conservative substitutions" for corresponding residues in a reference sequence are those that are physically or functionally similar to the corresponding reference residues, e.g., that have similar size, shape, electric charge, chemical properties including the ability to form covalent or hydrogen bonds, or the like. Particularly preferred conservative substitutions are those fulfilling the criteria defined for an "accepted point mutation" in Dayhoff et al. (1978), 5 Atlas of Protein Sequence and Structure. Suppl. 3, ch. 22 (pp. 354-352), Natl. Biomed. Res. Found., Washington, D.C. 20007, the teachings of which are incorporated by reference herein. In certain embodiments, a polypeptide suspected of being functionally equivalent to a reference morphogen polypeptide is aligned therewith using the method of Needleman, et al. (1970), J. Mol. Biol. 48:443-453, implemented conveniently by computer programs such as the Align program (DNAstar, Inc.). As noted above, internal gaps and amino acid insertions in the candidate sequence are ignored for purposes of calculating the defined relationship, conventionally expressed as a level of amino acid sequence homology or identity, between the candidate and reference sequences. "Amino acid sequence homology" is understood herein to mean amino acid sequence similarity. Homologous sequences share identical or similar amino acid residues, where similar residues are conservative substitutions for, or "allowed point mutations" of, corresponding amino acid residues in an aligned reference sequence. Thus, a candidate polypeptide sequence that shares 70% amino acid homology with a reference sequence is one in which any 70% ofthe aligned residues are either identical to or are conservative substitutions ofthe corresponding residues in a reference sequence. Of particular interest herein are morphogens, which, when provided to the kidney of a mammal, induce or maintain the normal state of differentiation and growth of nephron units. Of still more particular interest herein are morphogens which, when administered to a mammal, prevent, inhibit or delay the development of compensatory hypertrophy, including glomerular hypertrophy and/or tubular hypertrophy. Such morphogens can be used to treat a mammal in, or at risk of, chronic renal failure by preventing, inhibiting or delaying the progressive loss of functional nephron units and the consequent progressive loss of renal function. The present invention alternatively can be practiced with methods and compositions comprising a moφhogen stimulating agent or morphogen inducer in lieu of a morphogen. A "morphogen inducer" is a compound that stimulates in vivo production, e.g., expression, of a therapeutically effective concentration of an endogenous morphogen in the body of a mammal sufficient to regenerate or maintain renal tissue and/or to inhibit additional loss thereof. Such compounds are understood to include substances which, when administered to a mammal, act on cells of tissue(s) or organ(s) that normally are competent to produce and/or secrete a morphogen encoded within the genome ofthe mammal, and which cause the endogenous level ofthe moφhogen in the mammal's body to be altered. Endogenous or administered morphogens can act as endocrine, paracrine or autocrine factors. That is, endogenous morphogens can be synthesized by the cells in which moφhogenetic responses are induced, by neighboring cells, or by cells of a distant tissue, in which circumstances the secreted endogenous morphogen is transported to the site of morphogenesis, e.g., by the individual's bloodstream. In preferred embodiments, the agent stimulates expression and/or secretion of an endogenous morphogen so as to increase amounts thereof in renal tissues. In still other embodiments, an agent which acts as an agonist of a morphogen receptor may be administered instead ofthe morphogen itself. An "agonist" of a receptor means a compound which binds to the receptor and for which such binding has a similar functional result as binding ofthe natural, endogenous ligand ofthe receptor. That is, the compound must, upon interaction with the receptor, produce the same or substantially similar transmembrane and/or intracellular effects as the endogenous ligand. Thus, an agonist of a morphogen receptor binds to the receptor and such binding has the same or a similar functional result as morphogen binding (e.g., induction of morphogenesis). The activity or potency of an agonist can be less than that of the natural ligand, in which case the agonist is said to be a "partial agonist," or it can be equal to or greater than that ofthe natural ligand, in which case it is said to be a "full agonist." Thus, for example, a small peptide or other molecule which can mimic the activity of a morphogen in binding to and activating the morphogen's receptor may be employed as an equivalent ofthe morphogen. Preferably the agonist is a full agonist, but partial morphogen receptor agonists may also be advantageously employed. Methods of identifying such agonists are known in the art and include assays for compounds which induce moφhogen-mediated responses (e.g., induction of differentiation of metanephric mesenchyme, induction of endochondral bone formation, and the like). Such an agent may also be referred to as a morphogen "mimic," "mimetic," or "analog." The OP/BMP renal therapeutic agents ofthe invention, or the morphogens, moφhogen inducers and agonists of moφhogen receptors ofthe invention, may be administered by any route of administration which is compatible with the selected agent, and may be formulated with any pharmaceutically acceptable carrier appropriate to the route of administration. Preferred routes of administration are parenteral and, in particular, intravenous, intraperitoneal, and renal intracapsular. Treatments are also preferably conducted over an extended period on an outpatient basis. Daily dosages ofthe renal therapeutic agents are expected to be in the range of about 0.01- 1000 μg/kg body weight, and more preferably about 10-300 μg/kg body weight, although precise dosages will vary depending upon the particular renal therapeutic agent employed and the particular subject's medical condition and history. Finally, in yet further embodiments, renal cells may be implanted into the kidney of a subject in, or at risk, chronic renal failure, or at risk of needing renal replacement therapy, in order to serve as a source of morphogen and/or to provide a source of additional functional renal tissue. These cells may be renal mesenchymal progenitor cells, or renal mesenchymal progenitor cells which have been induced to undergo metanephric differentiation. The cells may be derived from a donor (e.g., a tissue-type matched donor, sibling, identical twin), may be derived from a tissue culture (e.g., undifferentiated renal mesenchyme culture, fetal renal tissue culture), or may be explanted from the subject and then be re-implanted after proliferation and/or differentiation. Preferably, the cells are induced to undergo metanephric differentiation by treatment with a morphogen (e.g., OP-1) either before or after implantation. The treatments ofthe present invention are useful in preventing, inhibiting or delaying the progressive loss of functional nephron units, and the consequent progressive loss of renal function, which typify chronic renal failure. As such they are of great value in preventing or delaying the need for chronic dialysis or renal replacement therapy in subjects with chronic renal insufficiency, or reducing the necessary frequency of chronic renal dialysis in subjects with end- stage renal disease. As such, they are useful in prolonging the lives, and in maintaining the quality of life, of subjects at risk of, or already afflicted with, chronic renal failure. Brief Description ofthe Figures Figure 1. This figure is a bar graph showing average serum creatinine levels for groups of sham-operated ("SHAM") or partially nephrectomized ("Nx Contr" and "OP-1 ") rats. 5-6 months post-surgery, rats received injections of vehicle only ("Nx control" and "SHAM") or 1, 3, 10 or 50 μg/kg body weight of soluble OP-1 ("OP-1") three times a week for 4-8 weeks. Figure 2. This figure is a bar graph showing average serum urea levels for groups of sham-operated ("SHAM") or partially nephrectomized ("Nx Contr" and "OP-1") rats. 5-6 months post-surgery, rats received injections of vehicle only ("Nx control" and "SHAM") or 1, 3, 10 or 50 μg/kg body weight of soluble OP-1 ("OP-1") three times a week for 4-8 weeks. Figure 3. Panels A-C of this figure are micrographs of renal tissue from rats at lOx magnification. (A) Tissue from sham-operated rat. (B) Tissue from rat in chronic renal failure after 5/6 nephrectomy (Nx control). (C) Tissue from rat treated with OP-1 after 5/6 nephrectomy. Figure 4. Panels A-C of this figure are micrographs of renal tissue from rats at 40x magnification. (A) Tissue from sham-operated rat. (B) Tissue from rat in chronic renal failure after 5/6 nephrectomy (Nx control). (C) Tissue from rat treated with OP-1 after 5/6 nephrectomy. Figure 5. This figure is a line graph showing average serum creatinine levels over 9 weeks for groups of partially nephrectomized rats. 2-3 weeks post-surgery, rats received injections of vehicle only ("Control") or 10 μg/kg body weight of soluble OP-1 ("OP-l") 3 times per week. Figure 6. This figure is a line graph showing average creatinine clearance rates as a measure of GFR over 8 weeks for groups of partially nephrectomized rats. 2-3 weeks post- surgery, rats received injections of vehicle only ("Control") or 10 μg/kg body weight of soluble OP-1 ("OP-1 ") 3 times per week. Figure 7. Panels 7-1 through 7-12 of this figure are a tabular alignment ofthe amino acid sequences of various naturally occurring morphogens with a preferred reference sequence of human OP-1, residues 38-139 of SEQ ID NO: 4. Moφhogen polypeptides shown in this figure also are identified in the Sequence Listing. Detailed Description ofthe Invention I. Definitions In order to more clearly and concisely point out the subject matter ofthe claimed invention, the following definitions are provided for specific terms used in the following written description and appended claims. Renal therapeutic agent. As used herein, the term "renal therapeutic agent" means a polypeptide, or a functional variant of a polypeptide, comprising at least the C-terminal six- or seven-cysteine domain of a mammalian protein selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, and proteins which exhibit at least 70% or, more preferably, 75% or 80% amino acid sequence homology with the amino acid sequence of the seven-cysteine domain of human OP-1; and which is (a) capable of inducing chondrogenesis in the Reddi-Sampath ectopic bone assay (Sampath and Reddi (1981), Proc. Natl. Acad. Sci. (USA) 78:7599-7603) or a substantially equivalent assay, (b) capable of significantly preventing, inhibiting, delaying or alleviating the progressive loss of renal function in a standard animal model of chronic renal failure, or (c) capable of causing a clinically significant improvement in a standard marker of renal function when administered to a mammal in, or at risk of, chronic renal failure. As used herein, a percentage "homology" between two amino acid sequences indicates the percentage of amino acid residues which are identical or similar between the sequences and, as used herein, "similar" residues are "conservative substitutions" which fulfill the criteria defined for an "accepted point mutation" in Dayhoff et al. (1978), Atlas of Protein Sequence and Structure Vol. 5 (Suppl. 3), pp. 354-352, Natl. Biomed. Res. Found., Washington, D.C. Therapeutic efficacy. As used herein, a renal therapeutic agent ofthe invention is said to have "therapeutic efficacy," and an amount ofthe agent is said to be "therapeuticaUy effective," if administration of that amount ofthe agent is sufficient to cause a clinically significant improvement in a standard marker of renal function when administered to a mammalian subject (e.g., a human patient) in, or at risk of, chronic renal failure. Such markers of renal function are well known in the medical literature and include, without being limited to, rates of increase in BUN levels, rates of increase in serum creatinine, static measurements of BUN, static measurements of serum creatinine, glomerular filtration rates (GFR), ratios of BUN/creatinine, serum concentrations of sodium (Na+), urine/plasma ratios for creatinine, urine/plasma ratios for urea, urine osmolality, daily urine output, and the like (see, for example, Brenner and Lazarus (1994), in Harrison's Principles of Internal Medicine. 13th edition, Isselbacher et al., eds., McGraw Hill Text, New York; Luke and Strom (1994), in Internal Medicine. 4th Edition, J.H. Stein, ed., Mosby-Year Book, Inc. St. Louis.) Glomerular Filtration Rate (GFR). The "glomerular filtration rate" or "GFR" is proportional to the rate of clearance into urine of a plasma-borne substance which is not bound by serum proteins, is freely filtered across glomeruli, and is neither secreted nor reabsorbed by the renal tubules. Thus, as used herein, GFR preferably is defined by the following equation: II Y V GFR = conc P conc where U coπc is the urine concentration ofthe marker, P conc is the plasma concentration ofthe marker, and Fis the urine flow rate in ml/min. Optionally, GFR is corrected for body surface area. Thus, the GFR values used herein may be regarded as being in units of ml/min/1.73m 2 . The preferred measure of GFR is the clearance of inulin but, because ofthe difficulty of measuring the concentrations of this substance, the clearance of creatinine is typically used in clinical settings. For example, for an average size, healthy human male (70 kg, 20-40 yrs), a typical GFR measured by creatinine clearance is expected to be approximately 125 ml/min with plasma concentrations of creatinine of 0.7-1.5 mg/dL. For a comparable, average size woman, a typical GFR measured by creatinine clearance is expected to be approximately 115 ml/min with creatinine levels of 0.5-1.3 mg/dL. During times of good health, human GFR values are relatively stable until about age 40, when GFR typically begins to decrease with age. For subjects surviving to age 85 or 90, GFR may be reduced to 50% ofthe comparable values at age 40. Expected Glomerular Filtration Rate (GFR^Y An estimate ofthe "expected GFR" or "GFR ex p" may be provided based upon considerations of a subject's age, weight, sex, body surface area, and degree of musculature, and the plasma concentration of some marker compound (e.g., creatinine) as determined by a blood test. Thus, as an example, an expected GFR or GFRe Xp may be estimated as: GFR ~ ( l 40 ~ a Se) ^ weight (kg) ' XP ~ 72 x P ^ img/dl) This estimate does not take into consideration such factors as surface area, degree of musculature, or percentage body fat. Nonetheless, using plasma creatinine levels as the marker, this formula has been employed for human males as an inexpensive means of estimating GFR. Because creatinine is produced by striated muscle, the expected GFR or GFRe Xp of human female subjects is estimated by the same equation multiplied by 0.85 to account for expected differences in muscle mass. (See Lemann, et al. (1990) Am. J. Kidnev Dis. 16(3):236-243.) Broad Cast. Microscopic examination of urinary sediment for the presence of formed elements is a standard procedure in urinalysis. Amongst the formed elements which may be present in urine are cylindrical masses of agglutinated materials that typically represent a mold or "cast" ofthe lumen of a distal convoluted tubule or collecting tubule. In healthy human subjects, such casts typically have a diameter of 15-25 μm. In subjects with chronic renal failure, however, hypertrophy ofthe tubules may result in the presence of "broad casts" or "renal failure casts" which are 2-6 times the diameter of normal casts and often have a homogeneous waxy appearance. Thus, as used herein, a "broad cast" means a urinary sediment cast having a diameter of 2-6 times normal, or about 30-150 μm for human casts. Chronic. As used herein with respect to clinical indications such as urinary casts, measured GFR, or other markers of renal function, "chronic" means persisting for a period of at least three, and more preferably, at least six months. Thus, for example, a subject with a measured GFR chronically below 50% of GFRexp is a subject in which the GFR has been measured and found to be below 50% of GFR eXp in at least two measurements separated by at least three, and more preferably, by at least six months, and for which there is no medically sound reason to believe that GFR was substantially (e.g., 10%) higher during the intervening period. Subjects in. or at risk of. chronic renal failure. As used herein, a subject is said to be in, or at risk of, chronic renal failure, or at risk ofthe need for renal replacement therapy, if the subject is reasonably expected to suffer a progressive loss of renal function associated with progressive loss of functioning nephron units. Whether a particular subject is in, or at risk of, chronic renal failure is a determination which may routinely be made by one of ordinary skill in the relevant medical or veterinary art. Subjects in, or at risk of, chronic renal failure, or at risk ofthe need for renal replacement therapy, include but are not limited to the following: subjects which may be regarded as afflicted with chronic renal failure, end-stage renal disease, chronic diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, hereditary nephritis, and/or renal dysplasia; subjects having a biopsy indicating glomerular hypertrophy, tubular hypertrophy, chronic glomerulosclerosis, and/or chronic tubulointerstitial sclerosis; subjects having an ultrasound, MRI, CAT scan, or other non-invasive examination indicating renal fibrosis; subjects having an unusual number of broad casts present in urinary sediment; subjects having a GFR which is chronically less than about 50%, and more particularly less than about 40%, 30% or 20%, ofthe expected GFR for the subject; human male subjects weighing at least about 50 kg and having a GFR which is chronically less than about 50 ml/min, and more particularly less than about 40 ml/min, 30 ml/min or 20 ml/min; human female subjects weighing at least about 40 kg and having a GFR which is chronically less than about 40 ml/min, and more particularly less than about 30 ml/min, 20 ml/min or 10 ml/min; subjects possessing a number of functional nephron units which is less than about 50%, and more particularly less than about 40%, 30% or 20%, of the number of functional nephron units possessed by a healthy but otherwise similar subject; subjects which have a single kidney; and subjects which are kidney transplant recipients. II. Description ofthe Preferred Embodiments A. General The present invention depends, in part, upon the surprising discovery that administration of certain protein-based renal therapeutic agents to subjects in, or at risk of, chronic renal failure, can reduce mortality and/or morbidity rates, and prevent, inhibit, delay or alleviate the progressive loss of renal function which characterizes chronic renal failure. Alternatively, or in addition, administration ofthe renal therapeutic agents ofthe present invention can prevent, inhibit or delay the progressive loss of functional nephron units and the progressive decline in glomerular filtration rate (GFR) which slowly but inevitably leads to the need for renal replacement therapy (i.e., renal transplant or chronic dialysis) or death. In preferred embodiments, the therapeutic agents ofthe invention are members ofthe osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins. B. Renal Therapeutic Agents The renal therapeutic agents ofthe present invention are naturally occurring proteins, or functional variants of naturally occurring proteins, in the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins. That is, these proteins form a distinct subgroup, referred to herein as the "OP/BMP family," within the loose evolutionary grouping of sequence-related proteins known as the TGF-β superfamily. Members of this protein family comprise secreted polypeptides that share common structural features, and that are similarly processed from a pro-protein to yield a carboxy-terminal mature protein. Within the mature protein, all members share a conserved pattern of six or seven cysteine residues defining a 97-106 amino acid domain, and the active form of these proteins is either a disulfide-bonded homodimer of a single family member, or a heterodimer of two different members (see, e.g., Massague (1990), Annu. Rev. Cell Biol. 6:597; Sampath et al. (1990), J. Biol. Chem. 265: 13198). For example, in its mature, native form, natural-sourced human OP-1 is a glycosylated dimer typically having an apparent molecular weight of about 30-36 kDa as determined by SDS-PAGE. When reduced, the 30 kDa protein gives rise to two glycosylated peptide subunits having apparent molecular weights of about 16 kDa and 18 kDa. The unglycosylated protein has an apparent molecular weight of about 27 kDa. When reduced, the 27 kDa protein gives rise to two unglycosylated polypeptide chains, having molecular weights of about 14 kDa to 16 kDa. Typically, the naturally occurring OP/BMP proteins are translated as a precursor, having an N-terminal signal peptide sequence, a "pro" domain, and a "mature" protein domain. The signal peptide is typically less than 30 residues, and is cleaved rapidly upon translation at a cleavage site that can be predicted using the method of Von Heijne (1986), Nucleic Acids Research 14:4683-4691. The "pro" domain is variable both in sequence and in length, ranging from approximately 200 to over 400 residues. The pro domain is cleaved to yield the "mature" C-terminal domain of approximately 1 15-180 residues, which includes the conserved six- or seven-cysteine C-terminal domain of 97-106 residues. As used herein, the "pro form" of an OP/BMP family member refers to a protein comprising a folded pair of polypeptides, each comprising a pro domain in either covalent or noncovalent association with the mature domains of the OP/BMP polypeptide. Typically, the pro form ofthe protein is more soluble than the mature form under physiological conditions. The pro form appears to be the primary form secreted from cultured mammalian cells. The "mature form" ofthe protein refers to mature C-terminal domain which is not associated, either covalently or noncovalently, with the pro domain. Any preparation of OP-1 is considered to contain mature form when the amount of pro domain in the preparation is no more than 5% ofthe amount of "mature" C-terminal domain. OP/BMP family members useful herein include any ofthe known naturally-occurring native proteins including allelic, phylogenetic counterpart and other variants thereof, whether naturally-sourced or biosynthetically produced (e.g., including "muteins" or "mutant proteins"), as well as new, active members ofthe OP/BMP family of proteins. Particularly useful sequences include those comprising the C-terminal seven cysteine domains of mammalian, preferably human, human OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP8 and BMP9. Other proteins useful in the practice ofthe invention include active forms of GDF-5, GDF-6, GDF-7, DPP, Vgl, Vgr-1, 60A, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, BMP 10, BMP11, BMP 13, BMP 15, UNI VIN, NODAL, SCREW, ADMP or NURAL and amino acid sequence variants thereof. In one currently preferred embodiment, the renal therapeutic agents ofthe invention are selected from any one of: OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, and BMP9. Publications disclosing these sequences, as well as their chemical and physical properties, include: OP-1 and OP-2: U.S. Pat. No. 5,011,691, U.S. Pat. No. 5,266,683, and Ozkaynak et al. (1990), EMBO J. 9:2085-2093; OP-3: WO94/10203; BMP2, BMP3, and BMP4: U.S. Pat. No. 5,013,649, W091/18098, WO88/00205, and Wozney et al. (1988), Science 242: 1528-1534; BMP5 and BMP6: WO90/11366 and Celeste et al. (1991), Proc. Natl. Acad. Sci. (USA) 87:9843-9847; Vgr-1 : Lyons et al. (1989), Proc. Natl. Acad. Sci. (USA) 86: 4554-4558; DPP: Padgett et al. (1987). Nature 325:81-84; Vgl: Weeks (1987). Cell 51 :861-867; BMP-9: WO95/33830; BMP10: WO94/26893; BMP-11: W094/26892; BMP12: WO95/16035; BMP-13: WO95/16035; GDF-1 : WO92/00382 and Lee et al. (1991), Proc. Natl. Acad. Sci. (USA) 88:4250-4254: GDF-8: WO94/21681; GDF-9: WO94/15966; GDF-10: WO95/10539; GDF-11 : WO96/01845; BMP-15: WO96/36710; MP121 : WO96/01316; GDF-5 (CDMP-1, MP52): WO94/15949, WO96/14335, WO93/16099 and Storm et al. (1994), Nature 368:639- 643; GDF-6 (CDMP-2, BMP13): WO95/01801, W096/14335 and WO95/10635; GDF-7 (CDMP-3, BMP12): WO95/10802 and WO95/10635; BMP-3b: Takao, et al. (1996), Biochem. Biophvs. Res. Comm. 219:656-662; GDF-3: WO94/15965; 60A: Blaster et al. (1993), Cell 73:687-702 and GenBank accession number LI 2032. In another embodiment, useful proteins include biologically active biosynthetic constructs, including novel biosynthetic proteins and chimeric proteins designed using sequences from two or more known OP/BMP family proteins. See also the biosynthetic constructs disclosed in U.S. Pat. No. 5,011,691, the disclosure of which is incorporated herein by reference (e.g., COP-1, COP-3, COP-4, COP-5, COP-7, and COP-16). In other preferred embodiments, the renal therapeutic agents useful herein include therapeutically effective proteins in which the amino acid sequences comprise a sequence sharing at least 70% amino acid sequence "homology" and, preferably, 75% or 80% homology with the C-terminal seven cysteine domain present in the active forms of human OP-1 (i.e., residues 330-431, as shown in SEQ ID NO: 2 of U.S. Pat. No. 5,266,683). In other preferred embodiments, the renal therapeutic agents useful herein include therapeutically effective proteins in which the amino acid sequences comprise a sequence sharing at least 60% amino acid sequence identity and, preferably, 65% or 70% identity with the C-terminal seven cysteine domain present in the active forms of human OP-1. Thus, a candidate amino acid sequence thought to have therapeutic efficacy in the present invention can be aligned with the amino acid sequence ofthe C-terminal seven cysteine domain of human OP-1 using the method of Needleman et al. (1970), JL Mol. Biol. 48:443-453, implemented conveniently by computer programs such as the Align program (DNAstar, Inc.). As will be understood by those skilled in the art, homologous or functionally equivalent sequences include functionally equivalent arrangements ofthe cysteine residues within the conserved cysteine domain, including amino acid insertions or deletions which alter the linear arrangement of these cysteines, but do not materially impair their relationship in the folded structure ofthe dimeric protein, including their ability to form such intra- or inter-chain disulfide bonds as may be necessary for biological activity. Therefore, internal gaps and amino acid insertions in the candidate sequence are ignored for purposes of calculating the level of amino acid sequence homology or identity between the candidate and reference sequences. "Amino acid sequence homology" is understood herein to include both amino acid sequence identity and similarity. Thus, as used herein, a percentage "homology" between two amino acid sequences indicates the percentage of amino acid residues which are identical or similar between the sequences. "Similar" residues are "conservative substitutions" which fulfill the criteria defined for an "accepted point mutation" in Dayhoff et al. (1978), Atlas of Protein Sequence and Structure Vol. 5 (Suppl. 3), pp. 354-352, Natl. Biomed. Res. Found., Washington, D.C. Thus, "conservative substitutions" are residues that are physically or functionally similar to the corresponding reference residues, having similar size, shape, electric charge, and/or chemical properties such as the ability to form covalent or hydrogen bonds, or the like. Examples of conservative substitutions include the substitution of one amino acid for another with similar characteristics, e.g., substitutions within the following groups: (a) valine, glycine; (b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine. The term "conservative substitution" or "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid in a given polypeptide chain, provided that the resulting substituted polypeptide chain also has therapeutic efficacy in the present invention. The renal therapeutic agents ofthe invention are also characterized by biological activities which may be readily ascertained by those of ordinary skill in the art. Specifically, a renal therapeutic agent ofthe present invention is (a) capable of inducing chondrogenesis in the Reddi-Sampath ectopic bone assay (Sampath and Reddi (1981), Proc. Natl. Acad. Sci. (USA) 78:7599-7603) or a substantially equivalent assay, (b) capable of significantly preventing, inhibiting, delaying or alleviating the progressive loss of renal function in a standard animal model of chronic renal failure, or (c) capable of causing a clinically significant improvement in a standard marker of renal function when administered to a mammal in, or at risk of, chronic renal failure. The Reddi-Sampath ectopic bone assay is well known in the art as an assay of chondrogenic activity. The assay, which can be easily performed, is described and discussed in, for example, Sampath and Reddi (1981), Proc. Natl. Acad. Sci. (USA> 78:7599-7603; and Wozney (1989), "Bone Morphogenetic Proteins," Progress in Growth Factor Research 1 :267- 280. Many equivalent assays, using other animals and tissue sites, may be employed or developed by those of skill in the art to evaluate the biological activity ofthe renal therapeutic agents ofthe present invention. See, for example, the bioassays described in U.S. Pat. No. 5,226,683. The renal therapeutic agents ofthe present invention also may be tested in animal models of chronic renal failure. Mammalian models of chronic renal failure in, for example, mice, rats, guinea pigs, cats, dogs, sheep, goats, pigs, cows, horses, and non-human primates, may be created by causing an appropriate direct or indirect injury or insult to the renal tissues of the animal. Animal models of chronic renal failure may, for example, be created by performing a partial (e.g., 5/6) nephrectomy which reduces the number of functioning nephron units to a level which initiates compensatory renal hypertrophy, further nephron loss, and the progressive decline in renal function which characterizes chronic renal failure. Finally, the renal therapeutic agents ofthe present invention may be evaluated for their therapeutic efficacy in causing a clinically significant improvement in a standard marker of renal function when administered to a mammalian subject (e.g., a human patient) in, or at risk of, chronic renal failure. Such markers of renal function are well known in the medical literature and include, without being limited to, rates of increase in BUN levels, rates of increase in serum creatinine, static measurements of BUN, static measurements of serum creatinine, glomerular filtration rates (GFR), ratios of BUN/creatinine, serum concentrations of sodium (Na+), urine/plasma ratios for creatinine, urine/plasma ratios for urea, urine osmolality, daily urine output, and the like (see, for example, Brenner and Lazarus (1994), in Harrison's Principles of Internal Medicine. 13th edition, Isselbacher et al., eds., McGraw Hill Text, New York; Luke and Strom (1994), in Internal Medicine. 4th Edition, J.H. Stein, ed., Mosby-Year Book, Inc. St. Louis.) The renal therapeutic agents contemplated herein can be expressed from intact or truncated genomic or cDNA or from synthetic DNAs in prokaryotic or eukaryotic host cells. The dimeric proteins can be isolated from the culture media and/or refolded and dimerized in vitro to form biologically active compositions. Heterodimers can be formed in vitro by combining separate, distinct polypeptide chains. Alternatively, heterodimers can be formed in a single cell by co-expressing nucleic acids encoding separate, distinct polypeptide chains. See, for example, WO93/09229, or U.S. Pat. No. 5,411,941, for several exemplary recombinant heterodimer protein production protocols. Currently preferred host cells include, without limitation, prokaryotes including E. coli. or eukaryotes including yeast, Saccharomyces. insect cells, or mammalian cells, such as CHO, COS or BSC cells. One of ordinary skill in the art will appreciate that other host cells can be used to advantage. Detailed descriptions ofthe proteins useful in the practice of this invention, including how to make, use and test them for chondrogenic activity, are disclosed in numerous publications, including U.S. Pat. Nos. 5,266,683 and 5,011,691, the disclosures of which are herein incorporated by reference. C. Morphogens. Inducers and Agonists Table 1, below, summarizes various naturally occurring members ofthe OP/BMP family identified to date, including their nomenclature as used herein, their Sequence Listing references, and publication sources for the amino acid sequences for the full length proteins not included in the Sequence Listing. Each ofthe generic terms set forth in Table 1 is intended and should be understood to embrace the therapeutically effective proteins expressed from nucleic acids encoding the identified sequence mentioned below and set forth in the Sequence Listing, or an active fragment or precursor thereof, or a functional equivalent thereof such as a naturally occurring or biosynthetic variant. Naturally occurring variants include allelic variant forms isolated from other individuals of a single biological species, as well as species variants (homologues) isolated from phylogenetically distinct biological species. TABLE 1 "OP-1 " Refers generically to mammalian proteins equivalent to the human OP-1 protein disclosed in SEQ ID NO: 4 ("hOP-1"), and includes at least mouse OP-1, SEQ ID NO: 5 ("mOP-1"). In each of human and mouse OP-1, SEQ ID NOs: 4 and 5, the conserved C-terminal seven cysteine domain is defined by residues 38 to 139. cDNA sequences and corresponding amino acid sequences for the full length proteins are provided in SEQ ID NOs: 15 and 16 (hOP-1) and SEQ ID NOs: 17 and 18 (mOP-1.) The mature proteins are defined by residues 293-431 (hOP-1) and 292-430 (mOP-1). The "pro" regions ofthe proteins, cleaved to yield the mature proteins are defined essentially by residues 30-292 (hOP-1) and residues 30-291 (mOP-1). "OP-2" Refers generically to mammalian proteins equivalent to the human OP-2 protein disclosed in SEQ ID NO: 6 ("hOP-2"), and includes at least mouse OP-2 ("mOP- 2", SEQ ID NO: 7). In each of human and mouse OP-2, the conserved C-terminal seven domain is defined by residues 38 to 139 of SEQ ID NOs: 6 and 7. cDNA sequences and corresponding amino acid sequences for the full length proteins are provided in SEQ ID NOs: 19 and 20 (hOP-2) and SEQ ID NOs: 21 and 22 (mOP- 2.) The mature proteins are defined essentially by residues 264-402 (hOP-2) and 261-399 (mOP-2). The "pro" regions ofthe proteins, cleaved to yield the mature proteins are defined essentially by residues 18-263 (hOP-2) and residues 18-260 (mOP-1). "OP-3" Refers generically to mammalian proteins equivalent to the mouse OP-3 protein disclosed in SEQ ID NO: 26 ("mOP-3"). The conserved C-terminal seven domain is defined by residues 298 to 399 of SEQ ID NO: 26, which shares greater than 79% amino acid identity with the corresponding mOP-2 and hOP-2 sequences, and greater than 66% identity with the corresponding OP-1 sequences. A cDNA sequence encoding the above-mentioned amino acid sequence is provided in SEQ ID NO: 25. OP-3 is unique among the morphogens identified to date in that the residue at position 9 in the conserved C-terminal seven domain (e.g., residue 315 of SEQ ID NO: 26) is a serine, whereas other morphogens typically have a tryptophan at this location. "BMP-2" Refers generically to mammalian proteins equivalent to the BMP-2 proteins, including at least human BMP-2 (or CBMP-2A, SEQ ID NO: 8). The amino acid sequence for the full length proteins, referred to in the literature as BMP-2 or BMP-2A, appear in Wozney, et al. (1988) Science 242: 1528-1534. The pro domain for BMP-2 (BMP-2A) likely includes residues 25-248; the mature protein, residues 249-396. "BMP-4" Refers generically to mammalian proteins equivalent to the CBMP-4 proteins, including at least human BMP-4 (or BMP-2B, SEQ ID NO 9) The amino acid sequence for the full length proteins, referred to in the literature as BMP-4 and BMP-2B, appear in Wozney, et al (1988) Science 242 1528-1534 The pro domain for BMP-4 (BMP-2B) likely includes residues 25-256, the mature protein, residues 257-408 "DPP" refers to proteins encoded by a Drosophila DPP gene and defining a conserved C- terminal seven domain (SEQ ID NO 10) The amino acid sequence for the full length protein appears in Padgett, et al (1987) Nature 325 81-84 The pro domain likely extends from the signal peptide cleavage site to residue 456; the mature protein likely is defined by residues 457-588 "Vgl" refers to proteins encoded by a Xenopus Vgl gene and defining a conserved C- terminal seven domain (SEQ ID NO 1 1) The amino acid sequence for the full length protein appears in Weeks (1987) Cell 51 861 -867 The prodomain likely extends from the signal peptide cleavage site to residue 246, the mature protein likely is defined by residues 247-360 "Vgr-1 " refers to proteins encoded by a murine Vgr-1 gene and defining a conserved C- terminal seven domain (SEQ ID NO 12) The amino acid sequence for the full length protein appears in Lyons, et al ( 1989) PNAS 86 4554-4558 The prodomain likely extends from the signal peptide cleavage site to residue 299, the mature protein likely is defined by residues 300-438 "GDF-1 " refers to proteins encoded by a human GDF-1 gene and defining a conserved C- terminal seven domain (SEQ ID NO 13) The cDNA and encoded amino sequence for the full length protein are provided in SEQ ID NOs 30 and 31. The prodomain likely extends from the signal peptide cleavage site to residue 214, the mature protein likely is defined by residues 215-372 "60A" refers generically to proteins expressed from a nucleic acid (e.g., the Drosophila 60 A gene) encoding a 60 A protein or active fragments thereof (see SEQ ID NOs: 23 and 24 wherein the cDNA and encoded amino acid sequence for the full length protein are provided). The conserved C-terminal seven domain is defined by residues 354 to 455 of SEQ ID NO: 24. The prodomain likely extends from the signal peptide cleavage site to residue 324; the mature protein likely is defined by residues 325-455. The 60A protein is considered likely to be a phylogenetic counteφart ofthe human and mouse OP-1 genes; Sampath, et al. (1993) PNAS 90:6004-6008. "BMP-3" refers to proteins encoded by a human BMP-3 gene and defining a conserved C- terminal seven domain (SEQ ID NO: 26). The amino acid sequence for the full length protein appears in Wozney, et al. (1988) Science 242: 1528-1534. The pro domain likely extends from the signal peptide cleavage site to residue 290; the mature protein likely is defined by residues 291-472. "BMP-5" refers to proteins encoded by a human BMP-5 gene and defining a conserved C- terminal seven domain (SEQ ID NO: 27). The amino acid sequence for the full length protein appears in Celeste, et al. (1991) PNAS 87:9843-9847. The pro domain likely extends from the signal peptide cleavage site to residue 316; the mature protein likely is defined by residues 317-454. "BMP-6" refers to proteins encoded by a human BMP-6 gene and defining a conserved C- terminal seven domain (SEQ ID NO: 28). The amino acid sequence for the full length protein appears in Celeste, et al. (1990) PNAS 87:9843-5847. The pro domain likely includes extends from the signal peptide cleavage site to residue 374; the mature sequence likely includes residues 375-513. As shown in Figure 7, the OP-2 and OP-3 proteins have an additional cysteine residue in the conserved C-terminal region (e.g., see residue 41 of SEQ ID NOs: 6 and 7). The GDF-1 protein has a four amino acid insert within the conserved C-terminal cysteine domain (residues 44-47 of SEQ ID NO: 13). Further, the BMP-2 and BMP-4 proteins are missing one amino acid residue within the cysteine domain. Thus, the alignment of these amino acid sequences in Figure 7 illustrates the principles of alignment used herein with respect to the preferred reference sequence of human OP-1, residues 38-139 of SEQ ID NO: 4. In addition to the OP/BMP renal therapeutic agents described in the previous section, the present invention may be practiced using "morphogens," as defined herein. Moφhogens useful in the present invention include those in which the amino acid sequences of morphogen polypeptides comprise a sequence sharing at least 70% amino acid sequence homology or "similarity", and preferably 80% homology or similarity with a reference sequence selected from the foregoing naturally OP/BMP family members. Preferably, the reference protein is human OP-1 , and the reference sequence thereof is the C-terminal seven cysteine domain present in active forms of human OP-1, residues 38-139 of SEQ ID NO 4. Morphogens useful herein accordingly include allelic, phylogenetic counterpart and other variants ofthe preferred reference sequence, whether naturally-occurring or biosynthetically produced (e.g., including "muteins" or "mutant proteins"), as well as novel members ofthe OP/BMP family of proteins set forth and identified above, e.g., in connection with Table 1. Certain particularly preferred moφhogen polypeptides share at least 60% amino acid identity with the preferred reference sequence of human OP-1, still more preferably at least 65% amino acid identity therewith. In other preferred embodiments, the moφhogen polypeptides useful in the present invention are defined by a generic amino acid sequence. For example, Generic Sequence 7 (SEQ ID NO: 1) and Generic Sequence 8 (SEQ ID NO: 2) disclosed below, accommodate the homologies shared among preferred OP/BMP protein family members identified to date, including at least OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, 60A, DPP, Vgl, BMP-5, BMP-6, Vgr-1, and GDF-1 (SEQ ID NOs: 4-15, 24, and 26-29). The generic sequences include both the amino acid identity shared by these sequences in the C-terminal domain, defined by the six and seven cysteine domains (Generic Sequences 7 and 8, respectively), as well as alternative residues for the variable positions within the sequence. The generic sequences provide an appropriate cysteine domain where inter- or intramolecular disulfide bonds can form, and contain certain critical amino acids likely to influence the tertiary structure ofthe folded proteins. In addition, the generic sequences allow for an additional cysteine at position 41 (Generic Sequence 7) or position 46 (Generic Sequence 8), thereby encompassing the active sequences of OP-2 and OP-3. Generic Sequence 7 Leu Xaa Xaa Xaa Phe Xaa Xaa 1 5 Xaa Gly Trp Xaa Xaa Xaa Xaa Xaa Xaa Pro 10 15 Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly 20 25 Xaa Cys Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa 30 35 Xaa Xaa Xaa Asn His Ala Xaa Xaa Xaa Xaa 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 Xaa Xaa Xaa Cys Cys Xaa Pro Xaa Xaa Xaa 60 65 Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa 70 75 Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Xaa Xaa 80 85 Xaa Met Xaa Val Xaa Xaa Cys Xaa Cys Xaa 90 95 wherein each Xaa independently is selected from a group of one or more specified amino acids defined as follows: "Res." means "residue" and Xaa at res.2 = (Tyr or Lys); Xaa at res.3 = Val or Ile); Xaa at res.4 = (Ser, Asp or Glu); Xaa at res.6 = (Arg, Gin, Ser, Lys or Ala); Xaa at res.7 = (Asp or Glu); Xaa at res.8 = (Leu, Val or Ile); Xaa at res.11 = (Gin, Leu, Asp, His, Asn or Ser); Xaa at res.12 = (Asp, Arg, Asn or Glu); Xaa at res. 13 = (Trp or Ser); Xaa at res.14 = (Ile or Val); Xaa at res.15 = (Ile or Val); Xaa at res.16 (Ala or Ser); Xaa at res.18 = (Glu, Gin, Leu, Lys, Pro or Arg); Xaa at res.19 = (Gly or Ser); Xaa at res.20 = (Tyr or Phe); Xaa at res.21 = (Ala, Ser, Asp, Met, His, Gin, Leu or Gly); Xaa at res.23 = (Tyr, Asn or Phe); Xaa at res.26 = (Glu, His, Tyr, Asp, Gin, Ala or Ser); Xaa at res.28 = (Glu, Lys, Asp, Gin or Ala); Xaa at res.30 = (Ala, Ser, Pro, Gin, Ile or Asn); Xaa at res.31 = (Phe, Leu or Tyr); Xaa at res.33 = (Leu, Val or Met); Xaa at res.34 = (Asn, Asp, Ala, Thr or Pro); Xaa at res.35 = (Ser, Asp, Glu, Leu, Ala or Lys); Xaa at res.36 = (Tyr, Cys, His, Ser or Ile); Xaa at res.37 = (Met, Phe, Gly or Leu); Xaa at res.38 = (Asn, Ser or Lys); Xaa at res.39 = (Ala, Ser, Gly or Pro); Xaa at res.40 = (Thr, Leu or Ser); Xaa at res.44 = (Ile, Val or Thr); Xaa at res.45 = (Val, Leu, Met or Ile); Xaa at res.46 = (Gin or Arg); Xaa at res.47 = (Thr, Ala or Ser); Xaa at res.48 = (Leu or Ile); Xaa at res.49 = (Val or Met); Xaa at res.50 = (His, Asn or Arg); Xaa at res.51 = (Phe, Leu, Asn, Ser, Ala or Val); Xaa at res.52 = (Ile, Met, Asn, Ala, Val, Gly or Leu); Xaa at res.53 = (Asn, Lys, Ala, Glu, Gly or Phe); Xaa at res.54 = (Pro, Ser or Val); Xaa at res.55 = (Glu, Asp, Asn, Gly, Val, Pro or Lys); Xaa at res.56 = (Thr, Ala, Val, Lys, Asp, Tyr, Ser, Gly, Ile or His), Xaa at res 57 = (Val, Ala or Ile); Xaa at res 58 = * (Pro or Asp), Xaa at res 59 = (Lys, Leu or Glu), Xaa at res 60 = (Pro, Val or Ala), Xaa at res 63 = (Ala or Val), Xaa at res 65 = (Thr, Ala or Glu), Xaa at res 66 = (Gin, Lys, Arg or Glu); Xaa at res 67 = (Leu, Met or Val), Xaa at res 68 = (Asn, Ser, Asp or Gly), Xaa at res 69 = (Ala, Pro or Ser), Xaa at res 70 = (Ile, Thr, Val or Leu), Xaa at res 71 = (Ser, Ala or Pro), Xaa at res.72 = (Val, Leu, Met or Ile), Xaa at res 74 = (Tyr or Phe), Xaa at res 75 = (Phe, Tyr, Leu or His), Xaa at res 76 = (Asp, Asn or Leu), Xaa at res 77 = (Asp, Glu, Asn, Arg or Ser), Xaa at res 78 = (Ser, Gin, Asn, Tyr or Asp); Xaa at res 79 = (Ser, Asn, Asp, Glu or Lys); Xaa at res 80 = (Asn, Thr or Lys), Xaa at res 82 = (Ile, Val or Asn), Xaa at res 84 = (Lys or Arg), Xaa at res 85 = (Lys, Asn, Gin, His, Arg or Val), Xaa at res 86 = (Tyr, Glu or His), Xaa at res 87 ** = (Arg, Gin, Glu or Pro), Xaa at res 88 = (Asn, Glu, Trp or Asp), Xaa at res 90 = (Val, Thr, Ala or Ile), Xaa at res.92 = (Arg, Lys, Val, Asp, Gin or Glu), Xaa at res 93 = (Ala, Gly, Glu or Ser), Xaa at res 95 = (Gly or Ala) and Xaa at res 97 = (His or Arg) Generic Sequence 8 (SEQ ID NO 2) includes all of Generic Sequence 7 and in addition includes the following sequence (SEQ ID NO 14) at its N-terminus Cys Xaa Xaa Xaa Xaa 1 5 Accordingly, beginning with residue 7, each "Xaa" in Geneπc Sequence 8 is a specified amino acid defined as for Generic Sequence 7, with the distinction that each residue number described for Generic Sequence 7 is shifted by five in Generic Sequence 8 Thus, "Xaa at res 2 =(Tyr or Lys)" in Generic Sequence 7 refers to Xaa at res 7 in Generic Sequence 8 In Generic Sequence 8, Xaa at res 2 = (Lys, Arg, Ala or Gin), Xaa at res 3 = (Lys, Arg or Met), Xaa at res 4 = (His, Arg or Gin), and Xaa at res 5 = (Glu, Ser, His, Gly, Arg, Pro, Thr, or Tyr) As noted above, certain currently preferred moφhogen polypeptide sequences useful in this invention have greater than 60% identity, preferably greater than 65% identity, with the amino acid sequence defining the preferred reference sequence of hOP-1 These particularly preferred sequences include allelic and phylogenetic counteφart variants ofthe OP-1 and OP-2 proteins, including the Drosophila 60A protein Accordingly, in certain particularly preferred embodiments, useful moφhogens include active proteins comprising pairs of polypeptide chains within the generic amino acid sequence herein referred to as "OPX" (SEQ ID NO 3), which defines the seven cysteine domain and accommodates the homologies between several identified variants of OP-1 and OP-2. As described therein, each Xaa at a given position independently is selected from the residues occurring at the corresponding position in the C-terminal sequence of mouse or human OP-1 or OP-2 (see SEQ ID NOs: 4-7 and/or SEQ ID NOs: 15-22). In still other preferred embodiments, useful moφhogen polypeptides have amino acid sequences comprising a sequence encoded by a nucleic acid that hybridizes, under stringent hybridization conditions, to DNA or RNA encoding reference morphogen sequences, e.g., C- terminal sequences defining the conserved C-terminal seven domains of OP-1 or OP-2, e.g., nucleotides 1036-1341 and nucleotides 1390-1695 of SEQ ID NO: 15 and 19, respectively. As used herein, stringent hybridization conditions are defined as hybridization according to known techniques in 40% formamide, 5 X SSPE, 5 X Denhardt's Solution, and 0.1% SDS at 37°C overnight, and washing in 0.1 X SSPE, 0.1% SDS at 50°C. As noted above, morphogens useful in the present invention generally are dimeric proteins comprising a folded pair of the above polypeptides. Morphogens are inactive when reduced, but are active as oxidized homodimers and when oxidized in combination with other morphogens of this invention to produce heterodimers. Thus, members of a folded pair of moφhogen polypeptides in a moφhogenically active protein can be selected independently from any ofthe specific morphogen polypeptides mentioned above. As noted above, a protein is morphogenic herein generally if it induces the developmental cascade of cellular and molecular events that culminate in the formation of new, organ-specific tissue. The morphogens generally are competent to induce all ofthe following biological functions in a moφhogenically permissive environment: stimulating proliferation of progenitor cells; stimulating the differentiation of progenitor cells; stimulating the proliferation of differentiated cells; and supporting the growth and maintenance of differentiated cells. The morphogens useful in the methods, compositions and devices of this invention include proteins comprising any ofthe polypeptide chains described above, whether isolated from naturally-occurring sources, or produced by recombinant DNA or other synthetic techniques, and includes allelic and phylogenetic counteφart variants of these proteins, as well as biosynthetic variants (muteins) thereof, and various truncated and fusion constructs. Deletion or addition mutants also are envisioned to be active, including those which may alter the conserved C- terminal six or seven cysteine domain, provided that the alteration does not functionally disrupt the relationship of these cysteines in the folded structure. Accordingly, such active forms are considered the equivalent ofthe specifically described constructs disclosed herein. The proteins may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of native or biosynthetic proteins, produced by expression of recombinant DNA in host cells. Figure 7 herein sets forth an alignment ofthe amino acid sequences ofthe active regions of naturally occurring proteins that have been identified or appreciated herein as OP/BMP renal therapeutic agents, including human OP-1 (hOP-1, SEQ ID NOs: 4 and 15-16), mouse OP-1 (mOP-1, SEQ ID NOs: 5 and 17-18), human and mouse OP-2 (SEQ ID NOs: 6, 7, and 19-22), mouse OP-3 (SEQ ID NOs: 25-26), BMP-2 (SEQ ID NO: 8), BMP-4 (SEQ ID NO: 9), BMP-3 (SEQ ID NO: 27), DPP (from Drosophila, SEQ ID NO: 10), Vgl, (from Xenopus, SEQ ID NO: 1 1), Vgr-1 (from mouse, SEQ ID NO: 12), GDF-1 (from mouse and/or human, SEQ ID NOs: 13, 30 and 31), 60A protein (from Drosophila, SEQ ID NOs: 23 and 24), BMP-5 (SEQ ID NO: 28) and BMP-6 (SEQ ID NO: 29). The sequences are aligned essentially following the method of Needleman, et al. (1970) J. Mol. Biol.. 48:443-453, calculated using the Align Program (DNAstar, Inc.). In Figure 7, three dots indicates that the amino acid in that position is the same as the corresponding amino acid in hOP-1. Three dashes indicates that no amino acid is present in that position, and are included for purposes of illustrating homologies. For example, amino acid residue 60 of BMP-2 (CBMP-2A) and BMP-4 (CBMP-2B) is "missing." Of course, both of these amino acid sequences in this region comprise Asn-Ser (residues 58, 59), with BMP- 2 then comprising Lys and Ile, whereas BMP-4 comprises Ser and Ile. Figure 7 also illustrates the handling of insertions in the morphogen amino acid sequence: between residues 56 and 57 of BMP-3 is an inserted Val residue; between residues 43 and 44 of GDF-1 is inserted the amino acid sequence, Gly-Gly-Pro-Pro. Such deviations from the reference morphogen sequence are ignored for puφoses of calculating the defined relationship between, e.g., GDF-1 and hOP-1. As is apparent from the amino acid sequence comparisons set forth in Figure 7, significant amino acid changes can be made from the reference sequence while retaining activity. For example, while the GDF-1 protein sequence depicted in Figure 7 shares only about 50% amino acid identity with the hOP-1 sequence described therein, the GDF-1 sequence shares greater than 70% amino acid sequence homology (or "similarity") with the hOP-1 sequence, where "homology" or "similarity" includes allowed conservative amino acid substitutions within the aligned sequence, e.g., as defined by Dayhoff, et al. (1979) 5 Atlas of Protein Sequence and Structure Suppl. 3, pp. 345- 362, (M O. Dayhoff, ed., Natl. BioMed. Res. Found., Washington D C ). Accordingly, in still another preferred aspect, the invention includes morphogens comprising species of polypeptide chains having the generic amino acid sequence referred to herein as "OPX", which defines the seven cysteine domain and accommodates the identities and homologies between the various identified OP-1 and OP-2 proteins. OPX is presented in SEQ ID NO: 3. As described therein, each Xaa at a given position independently is selected from the residues occurring at the corresponding position in the C-terminal sequence of mouse or human OP-1 or OP-2 (see Figure 7 and SEQ ED NOs: 4-7 and/or SEQ ID NOs: 15-22). In another set of embodiments, an effective amount of an agent competent to stimulate or induce increased endogenous expression of an OP/BMP renal therapeutic agent or morphogen in a mammal may be administered. For example, an agent competent to stimulate or induce OP-1 production and/or secretion from renal tissue may be provided to a mammal, e.g., by systemic administration to the mammal or by direct administration ofthe moφhogen-stimulating agent to renal tissue. Alternatively, the morphogen-stimulating agent or "morphogen inducer" may induce morphogen expression and/or secretion at a distant site (e.g., at a tissue locus other than renal tissue), with the expressed moφhogen circulating to renal tissue. A method for identifying and testing agents competent to modulate the levels of endogenous morphogens in a given tissue is described in detail in published applications WO93/05172 and WO93/05751, the teachings of which are incorporated herein by reference. Briefly, candidate compounds can be identified and tested by incubation in vitro with a test tissue or cells thereof, or a cultured cell line derived therefrom, for a time sufficient to allow the compound to affect the production, i.e., the expression and/or secretion, of a moφhogen produced by the cells of that tissue. Here, suitable tissue, or cultured cells of a suitable tissue, preferably can be selected from renal epithelium, fibroblasts, and osteoblasts. In another series of embodiments, an agent which acts as an agonist of an OP/BMP renal therapeutic agent or morphogen receptor may be administered instead ofthe OP/BMP renal therapeutic agent or morphogen itself. Such an agent may also be referred to an a morphogen "mimic," "mimetic," or "analog." Thus, for example, a small peptide or other molecule which can mimic the activity of an OP/BMP renal therapeutic agent or moφhogen in binding to and activating the OP/BMP renal therapeutic agent or morphogen's receptor may be employed as an equivalent ofthe OP/BMP renal therapeutic agent or moφhogen. Preferably the agonist is a full agonist, but partial receptor agonists may also be advantageously employed. Methods of identifying such agonists are known in the art and include assays for compounds which induce moφhogen-mediated responses (e.g., induction of differentiation of metanephric mesenchyme, induction of endochondral bone formation). For example, methods of identifying moφhogen inducers or agonists of moφhogen receptors may be found in U.S. Ser. No. 08/478,097 filed June 7, 1995 and U.S. Ser. No. 08/507,598 filed July 26, 1995, the disclosures of which are incoφorated herein by reference. Finally, in other embodiments cells may be implanted into the kidney of a subject in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, in order to serve as a source of an OP/BMP renal therapeutic agent or morphogen and/or to provide a source of additional functional renal tissue. Such cells may be host or donor cells which normally express OP/BMP renal therapeutic agents or moφhogens, which have been transformed so as to express OP/BMP renal therapeutic agents or morphogens, or which have been treated with OP/BMP renal therapeutic agents or morphogens. D. Subjects for Treatment As a general matter, the methods ofthe present invention may be utilized for any mammalian subject in, or at risk of, chronic renal failure, or at risk ofthe need for renal replacement therapy (i.e., chronic dialysis or renal transplant). Mammalian subjects which may be treated according to the methods ofthe invention include, but are not limited to, human subjects or patients. In addition, however, the invention may be employed in the treatment of domesticated mammals which are maintained as human companions (e.g., dogs, cats, horses), which have significant commercial value (e.g., dairy cows, beef cattle, sporting animals), which have significant scientific value (e.g., captive or free specimens of endangered species), or which otherwise have value. In addition, as a general matter, the subjects for treatment with the methods ofthe present invention need not present indications for treatment with an OP/BMP renal therapeutic agent or moφhogen other than those indications associated with risk of chronic renal failure. That is, the subjects for treatment are expected to be otherwise free of indications for treatment according to the present invention. In some number of cases, however, the subjects may present with other symptoms (e.g., osteodystrophy) for which treatment with an OP/BMP renal therapeutic agent or morphogen would be indicated. In such cases, the treatment should be adjusted accordingly so to avoid excessive dosing. One of ordinary skill in the medical or veterinary arts is trained to recognize subjects which may be at a substantial risk of chronic renal failure, or at substantial risk ofthe need for renal replacement therapy. In particular, clinical and non-clinical trials, as well as accumulated experience, relating to the presently disclosed and other methods of treatment, are expected to inform the skilled practitioner in deciding whether a given subject is in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, and whether any particular treatment is best suited to the subject's needs, including treatment according to the present invention. As a general matter, a mammalian subject may be regarded as being in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, if that subject has already been diagnosed as afflicted with, or would be regarded as being afflicted with, a condition which typically leads to progressive loss of renal function associated with progressive loss of functioning nephron units. Such conditions include, but are not limited to, chronic renal failure, end-stage renal disease, chronic diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, hereditary nephritis, renal dysplasia and the like. These, and other diseases and conditions known in the art, typically lead to a progressive loss of functioning nephrons and to the onset of chronic renal failure. Frequently, one of skill in the medical or veterinary arts may base a prognosis, diagnosis or treatment decision upon an examination of a renal biopsy sample. Such biopsies provide a wealth of information useful in diagnosing disorders ofthe kidney but, due to the invasiveness of the procedure, and the additional trauma to a presumably unhealthy kidney, may not be appropriate for all subjects. Nonetheless, subjects in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, may be recognized by histological indications from renal biopsies including, but not limited to, glomerular hypertrophy, tubular hypertrophy, glomerulosclerosis, tubulointerstitial sclerosis, and the like. Less invasive techniques for assessing kidney morphology include MRI, CAT and ultrasound scans. Scanning techniques are also available which employ contrasting or imaging agents (e.g., radioactive dyes) but, it should be noted, some of these are particularly toxic to renal tissues and structures and, therefore, their use may be ill-advised in subjects in, or at risk of, chronic renal failure. Such non-invasive scanning techniques may be employed to detect conditions such as renal fibrosis or sclerosis, focal renal necrosis, renal cysts, and renal gross hypertrophy which will place a subject in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy. Quite frequently, prognosis, diagnosis and/or treatment decisions are based upon clinical indications of renal function. One such indication is the presence in urinary sediment of an unusual number of "broad" or "renal failure" casts, which is indicative of tubular hypertrophy and suggests the compensatory renal hypertrophy which typifies chronic renal failure. A better indication of renal function is the glomerular flow rate (GFR), which can be measured directly by quantifying the rate of clearance of particular markers, or which may be inferred from indirect measurements. It should be noted that the present invention is not directed to the measurement of GFR or to the diagnosis of chronic renal failure. The methods of treatment ofthe present invention need not, therefore, be restricted to subjects presenting with any particular measures of GFR, or any other particular marker of renal function. Indeed, it is not necessary that the GFR of a subject, or any other particular marker of renal function, be determined before practicing the treatments of the present invention. Nonetheless, the measurement of GFR is considered to be a preferred means of assessing renal function. As is well known in the art, GFR reflects the rate of clearance of a reference or marker compound from the plasma to the urine. The marker compound to be considered is typically one which is freely filtered by the glomeruli, but which is not actively secreted or reabsorbed by the renal tubules, and which is not significantly bound by circulating proteins. The rate of clearance is typically defined by the formula, presented above, which relates the volume of urine produced in a twenty-four period, and the relative concentrations ofthe marker in the urine and plasma. To be more accurate, the GFR should also be corrected for body surface area. The "gold standard" reference compound is inulin because of its filtration properties and lack of serum-binding. The concentration of this compound is, however, difficult to quantify in blood or urine. The clearance rates of other compounds, including p-aminohippurate (PAH) and creatinine, are therefore often used instead of inulin. In addition, various formulas are often employed which seek to simplify the estimation of actual GFR by omitting considerations of actual urine concentrations ofthe marker, actual daily volumes of urine produced, or actual body surface area. These values may be replaced by estimates based on other factors, by baseline values established for the same subject, or by standard values for similar subjects. These estimates should be used with caution, however, as they may entail inappropriate assumptions based upon the renal function of normal or healthy subjects. Various methods and formulas have been developed in the art which describe an expected value of GFR for a healthy subject with certain characteristics. In particular, formulas are available which provide an expected value ofthe GFR based upon plasma creatinine levels, age, weight and sex. One such formula for an expected GFR is presented above. Other formulas may, of course, be employed and tables of standard values may be produced for subjects of a given age, weight, sex, and/or plasma creatinine concentration. Newer methods of measuring or estimating GFR (e.g., using NMR or MRI technologies) are also now available in the art and may be used in accordance with the present invention (see, e.g., U.S. Pat. Nos. 5,100,646 and 5,335,660). As a general matter, irrespective ofthe manner in which GFR is measured or estimated, a subject may be considered to be in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, when the subject has a GFR which is chronically less than about 50% ofthe expected GFR for that subject. The risk is considered greater as the GFR falls lower. Thus, a subject is increasingly considered at risk if the subject has a GFR which is chronically less than about 40%, 30% or 20% of the expected GFR. As a general matter, irrespective ofthe manner in which GFR is measured or estimated, a human male subject weighing at least about 50 kg may be considered to be in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, when the subject has a GFR which is chronically less than about 50 ml/min. The risk is considered greater as the GFR falls lower. Thus, a subject is increasingly considered at risk if the subject has a GFR which is chronically less than about 40, 30 or 20 ml/min. As a general matter, irrespective ofthe manner in which GFR is measured or estimated, a human female subject weighing at least about 40 kg may be considered to be in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, when the subject has a GFR which is chronically less than about 40 ml/min. The risk is considered greater as the GFR falls lower. Thus, a subject is increasingly considered at risk if the subject has a GFR which is chronically less than about 30, 20 or 10 ml/min. By a employing a variety of methods, including the histological examinations, non-invasive scanning procedures, evaluations of clinical indicators, and other techniques described above and known in the art, those in the medical and veterinary arts may provide estimates of either the number of functioning nephron units which a subject possesses, or the percentage of functioning nephron units which a subject possesses relative to a healthy but otherwise similar subject (e.g., a conspecific subject of approximately the same age, weight, and sex). Thus, for example, a biopsy may reveal a decrease in the density of functional nephrons, or imaging with filtered agents may indicate losses of functional renal tissue and/or filtering capacity. Such measures or estimates provide another means of expressing when a subject is in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy. Thus, as a general matter, a subject may be regarded 1 - 35 - to be in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, if that subject possesses a number of functional nephron units which is less than about 50% ofthe number of functional nephron units of a healthy, but otherwise similar, subject. As above, the risk is considered greater as the number of functional nephrons decreases further. Thus, a subject is increasingly considered at risk if the subject has a number of functional nephrons which is less than about 40, 30 or 20% ofthe number for a similar but healthy subject. Finally, it should be noted that subjects possessing a single kidney, irrespective ofthe manner of loss ofthe other kidney (e.g., physical trauma, surgical removal, birth defect), may be considered to be prima facie at risk of chronic renal failure, or the need for renal replacement therapy. This is particularly true for those subjects in which one kidney has been lost due to a disease or condition which may afflict the remaining kidney. Similarly, subjects which are already recipients of a renal transplant, or which are already receiving chronic dialysis (e.g., chronic hemodialysis or continuous ambulatory peritoneal dialysis) may be considered prima facie to be at risk of chronic renal failure, or the need for further renal replacement therapy. E. Formulations and Methods of Treatment The OP/BMP renal therapeutic agents, morphogens, morphogen inducers, or agonists of morphogen receptors ofthe present invention may be administered by any route which is compatible with the particular morphogen, inducer, or agonist employed. Thus, as appropriate, administration may be oral or parenteral, including intravenous, intraperitoneal, and renal intracapsular routes of administration. In addition, administration may be by periodic injections of a bolus ofthe agent, or may be made more continuous by intravenous or intraperitoneal administration from a reservoir which is external (e.g., an i.v. bag) or internal (e.g., a bioerodable implant). The therapeutic agents ofthe invention may be provided to an individual by any suitable means, preferably directly (e.g., locally, as by injection or topical administration to a tissue locus) or systemically (e.g., parenterally or orally). Where the agent is to be provided parenterally, such as by intravenous, subcutaneous, intramuscular, intraorbital, ophthalmic, intraventricular, intracranial, intracapsular, intraspinal, intracisternal, intraperitoneal, buccal, rectal, vaginal, intranasal or by aerosol administration, the agent preferably comprises part of an aqueous solution. The solution is physiologically acceptable so that in addition to delivery ofthe desired agent to the patient, the solution does not otherwise adversely affect the patient's electrolyte and/or volume balance. The aqueous medium for the agent thus may comprise normal physiologic saline (e.g., 9.85% NaCl, 0.15M, pH 7-7.4). Such an aqueous solution containing the agent can be made, for example, by dissolving the agent in 50% ethanol containing acetonitrile in 0.1% trifluoroacetic acid (TFA) or 0.1% HCl, or equivalent solvents. One volume ofthe resultant solution then is added, for example, to ten volumes of phosphate buffered saline (PBS), which further may include 0.1 -0.2% human serum albumin (HSA). The resultant solution preferably is vortexed extensively. If desired, an agent may be made more soluble by association with a suitable molecule. For example, association ofthe mature OP/BMP or morphogen dimer with the pro domain results in the pro form ofthe protein which typically is more soluble or dispersible in physiological solutions than the corresponding mature form. In fact, endogenous OP/BMP proteins are thought to be transported (e.g., secreted and circulated) in the mammalian body in this form. This soluble form ofthe protein can be obtained from culture medium of mammalian cells, e.g., cells transfected with nucleic acid encoding and competent to express the OP/BMP protein or morphogen. Alternatively, a soluble species can be formulated by complexing the mature dimer (or an active fragment thereof) with a pro domain or a solubility-enhancing fragment thereof (described more fully below). Another molecule capable of enhancing solubility and particularly useful for oral administrations, is casein. For example, addition of 0.2% casein increases solubility ofthe mature active form of OP-1 by 80%. Other components found in milk and/or various serum proteins also may be useful. Finally, as noted above, in another series of embodiments renal cells may be implanted into the kidney of a subject in, or at risk of, chronic renal failure, or at risk of needing renal replacement therapy, in order to serve as a source of an OP/BMP renal therapeutic agent or morphogen and/or to provide a source of additional functional renal tissue. These cells may be any compatible mammalian cells, including renal mesenchymal progenitor cells, or renal mesenchymal progenitor cells which have been induced to undergo metanephric differentiation. The cells may be derived from a donor (e.g., a tissue-type matched donor, sibling, identical twin), may be derived from a tissue culture (e.g., undifferentiated renal mesenchyme culture, fetal renal tissue culture), or may be explanted from the subject and then be re-implanted after proliferation and/or differentiation. Preferably, the cells are induced to undergo metanephric differentiation by treatment with an OP/BMP renal therapeutic agent or morphogen (e.g., OP-1) either before or after implantation. Thus, for example, renal mesenchymal progenitor cells may be explanted from a subject, allowed or caused to proliferate in vitro, be induced to undergo metanephric differentiation by morphogen treatment, and be re-implanted where they may provide a source of moφhogen and/or differentiate further into functional renal tissue. Practice ofthe invention, including additional preferred aspects and embodiments thereof, will be still more fully understood from the following examples, which are presented herein for illustration only and should not be construed as limiting the invention in any way. Examples Rat Remnant Kidnev Model A rat partial (5/6) nephrectomy or rat remnant kidney model (RRKM) model was employed essentially as described (Vukicevic, et al. (1987) J. Bone Mineral Res. 2:533). Male rats (2-3 months old, weighing about 150-200 g) were subjected to unilateral nephrectomy (either left or right kidney). After approximately one week, 2/3 of the remaining kidney was surgically removed. Immediately following surgery, plasma creatinine and BUN levels rise dramatically due to the loss of renal mass and function. Over the next several weeks of this "acute" failure phase, plasma creatinine and BUN levels of surviving animals decline somewhat toward normal values but remain elevated. Renal function then appears to remain relatively constant or stable for a period of variable duration. After this point, the animals enter a period of chronic renal failure in which there is an essentially linear decline in renal function ending in death. As surgical controls, additional rats were subjected to a "sham" operation in which the kidneys were decapsulated but no renal tissue was removed. Intervention Model for Chronic Renal Failure In this model, both nephrectomized and sham-operated rats were maintained for approximately 5-6 months after surgery. At this point, surviving nephrectomized animals were past the stable phase and had entered chronic renal failure. Rats were divided into 8 groups with 12 rats in each group. Two groups of nephrectomized rats were used as controls (Nx controls), with one of those groups receiving no treatment at all, while the other received injections of only the vehicle buffer. In addition, two groups of sham-operated rats were used as controls (sham controls), with one group receiving only the vehicle buffer, while the other received soluble OP-1 (sOP-1) at 10 μg/kg body weight. Four experimental groups of nephrectomized rats were employed, receiving sOP-1 at 1, 3, 10 or 50 μg/kg body weight by intraperitoneal injection (OP-1 Nx animals). OP-1 treated and vehicle- only rats received three injections per week for 4-8 weeks. Total injection volume was 300 μl. No statistically significant differences were observed between the two Nx control groups or between the two sham control groups. Compared to the sham group receiving only vehicle, the Nx control receiving only vehicle demonstrated significantly (p < 0.01) elevated serum creatinine (Figure 1) at the end ofthe study, indicating a significant loss of renal function. Although nephrectomized rats treated with either 1 or 3 μg/kg body weight sOP-1 did not show significantly reduced serum creatinine when compared to the Nx control, nephrectomized rats treated with sOP-1 at doses of 10 or 50 μg/kg body weight showed significant (p < 0.05) reductions in creatinine values (Figure 1). Similar results were observed for serum urea levels: Although nephrectomized rats treated with either 1 or 3 μg/kg body weight sOP-1 did not show significantly reduced serum urea when compared to the Nx control, nephrectomized rats treated with sOP-1 at doses of 10 or 50 μg/kg body weight showed significant (p < 0.01) reductions in serum urea values (Figure 2). All nephrectomized rats showed significantly (p < 0.01) higher serum urea when compared to the sham-operated rats (Figure 2). Histological observations indicate that, in contrast to the vehicle treated Nx control group, OP-1 treated nephrectomized rats exhibit relatively normal glomerular histology,. Figure 3, for example, shows typical renal samples from (A) normal rat kidney, (B) untreated Nx control animals, and (C) OP-1 treated nephrectomized rats under low magnification (lOx). Figure 4 shows similar samples under higher magnification (40x). Histomorphometric analysis indicates that OP-1 Nx rats showed reduced incidence of glomerular sclerosis and loop collapse, relatively scattered sclerosis and microaneurysms, and more viable glomeruli compared to Nx control rats (Table 2). None ofthe rats died in any group during this study. Prophylactic Model for Chronic Renal Failure Rats were subjected to partial nephrectomies or sham-operated as described above. In this model, in order to test the ability of OP/BMP renal therapeutic agents to prevent, inhibit or delay the initiation of chronic renal failure, the rats were allowed to recover for approximately two weeks after surgery before initiation of OP-1 therapy. At this point, surviving animals were past the acute renal failure phase and had not yet entered chronic renal failure. Rats were divided into two groups of 15-20 rats. One group received only vehicle buffer (Nx control) whereas the other received OP-1 treatment at 10 μg/kg body weight given intraperitoneally three times per week. Administration of OP-1 or vehicle continued for a period of approximately 8-9 weeks. During weeks 1-5 of treatment, both groups showed elevated serum creatinine (> 100 μmol/L) relative to sham-operated controls (35 + 7 μmol/L). At about 5 weeks, both groups began to show a rise in serum creatinine suggesting the onset of progressive or chronic renal failure. The rise in serum creatinine was, however, markedly less rapid in the OP-1 treated group and was significantly lower than in the Nx controls (Figure 5: p < 0.02 at weeks 6 and 8; p < 0.01 at weeks 7 and 9). Similar results were observed in serum BUN values as well. More important, measurements of GFR, based on serum and urine creatinine values, showed a highly significant decrease in both groups of nephrectomized rats (< 1.8 ml/min) relative to sham-operated controls (4.7 ± 1.1 ml/min). The GFR in both groups continued to decline during weeks 1-3 of treatment. At approximately three weeks, however, GFR in the OP-1 treated group stabilized whereas the decline in renal function continued in the Nx controls. By week 5, the difference in GFR values between OP-1 treated and Nx control rats had become statistically significant (p < 0.02). This difference in GFR continued to increase over time (p < 0.01 at week 6; p < 0.001 at weeks 7 and 8), as the Nx controls continued to decline but the OP-1 treated rats remained stable (Figure 6). By the end of 9 weeks, 40% ofthe Nx control rats were dead whereas none ofthe OP-1 treated rats had died. Histological evaluation of tissue sections confirmed that OP-1 treated rats showed greater preservation or maintenance of glomeruli, as well as proximal and distal tubule structures. There were also signs in the OP-1 treated rats of nephrogenic mesenchymal condensations and the appearance of developmental nephrogenic structures. Table 2 reports results of several standard quantitative (e.g., PAS-staining of extracellular matrix) and semi-quantitative (e.g., visual ranking) histomorphometric measures obtained for tissue slices from Nx control and OP-1 treated Nx rats. These results indicate that OP-1 treatment of nephrectomized rates resulted in overall improvement (or reduced degeneration) of kidney tissue morphology, increased mesangial or perivascular thickening, decreased glomerular sclerosis and loop collapse, decreased presence of "scattered" sclerosis and microaneurysms, and an increase in viable glomeruli. TABLE 2 Equivalents The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope ofthe invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency ofthe claims are intended to be embraced therein. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: CREATIVE BIOMOLECULES, INC. (B) STREET: 45 SOUTH STREET (C) CITY: HOPKINTON (D) STATE: MA (E) COUNTRY: USA (F) POSTAL CODE (ZIP) : 01748 (G) TELEPHONE: 1-508-435-9001 (H) TELEFAX: 1-508-435-0454 (I) TELEX: (ii) TITLE OF INVENTION: MORPHOGEN TREATMENT FOR CHRONIC RENAL FAILURE (iii) NUMBER OF SEQUENCES: 31 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: CREATIVE BIOMOLECULES, INC. (B) STREET: 45 SOUTH STREET (C) CITY: HOPKINTON (D) STATE: MA (E) COUNTRY: USA (F) ZIP:- 01748 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/643,321 (B) FILING DATE: 06-MAY-1996 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: TWOMEY, MICHAEL J (B) REGISTRATION NUMBER: 38,349 (C) REFERENCE/DOCKET NUMBER: CRP-118PC (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 617/248-7000 (B) TELEFAX: 617/248-7100 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 97 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein W 9 - 42 - ( ix) FEATURE : (A) NAME/KEY: Protein (B) LOCATION: 1..97 (D) OTHER INFORMATION: /label= Generic-Seq-7 /note= "wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification." (xi) SEQUENCE DESCRIPTION: SEQ ID N0:1: Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Pro 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Pro 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val Xaa Xaa Cys Xaa Cys 85 90 95 Xaa (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..102 (D) OTHER INFORMATION: /label= Generic-Seq-8 /note= "wherin each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Cys Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly 20 25 30 Xaa Cys Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Cys Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val 85 90 95 Xaa Xaa Cys Xaa Cys Xaa 100 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..102 (D) OTHER INFORMATION: /label= OPX /note= "WHEREIN EACH XAA IS INDEPENDENTLY SELECTED FROM A GROUP OF ONE OR MORE SPECIFIED AMINO ACIDS AS DEFINED IN THE SPECIFICATION" (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Cys Xaa Xaa His Glu Leu Tyr Val Xaa Phe Xaa Asp Leu Gly Trp Xaa 1 5 10 15 Asp Trp Xaa Ile Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys Glu Gly 20 25 30 Glu Cys Xaa Phe Pro Leu Xaa Ser Xaa Met Asn Ala Thr Asn His Ala 35 40 45 Ile Xaa Gin Xaa Leu Val His Xaa Xaa Xaa Pro Xaa Xaa Val Pro Lys 50 55 60 Xaa Cys Cys Ala Pro Thr Xaa Leu Xaa Ala Xaa Ser Val Leu Tyr Xaa 65 70 75 80 Asp Xaa Ser Xaa Asn Val Xaa Leu Xaa Lys Xaa Arg Asn Met Val Val 85 90 95 Xaa Ala Cys Gly Cys His 100 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 139 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (F) TISSUE TYPE: HIPPOCAMPUS (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..139 (D) OTHER INFORMATION: /label= hOPl-MATURE (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Ser Thr Gly Ser Lys Gin Arg Ser Gin Asn Arg Ser Lys Thr Pro Lys 1 5 10 15 Asn Gin Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser Ser 20 25 30 Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg 35 40 45 Asp Leu Gly Trp Gin Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala 50 55 60 Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn 65 70 75 80 Ala Thr Asn His Ala Ile Val Gin Thr Leu Val His Phe Ile Asn Pro 85 90 95 Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu Asn Ala Ile 100 105 110 Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr 115 120 125 Arg Asn Met Val Val Arg Ala Cys Gly Cys His 130 135 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 139 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: MURIDAE (F) TISSUE TYPE: EMBRYO (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..139 (D) OTHER INFORMATION: /label= MOPl-MATURE (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Ser Thr Gly Gly Lys Gin Arg Ser Gin Asn Arg Ser Lys Thr Pro Lys 1 5 10 15 Asn Gin Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn Ser Ser Ser 20 25 30 Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg 35 40 45 Asp Leu Gly Trp Gin Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala 50 55 60 Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn 65 70 75 80 Ala Thr Asn His Ala Ile Val Gin Thr Leu Val His Phe Ile Asn Pro 85 90 95 Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu Asn Ala Ile 100 105 110 Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr 115 120 125 Arg Asn Met Val Val Arg Ala Cys Gly Cys His 130 135 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 139 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: HOMO SAPIENS (F) TISSUE TYPE: HIPPOCAMPUS (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..139 (D) OTHER INFORMATION: /label= HOP2-MATURE (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Ala Val Arg Pro Leu Arg Arg Arg Gin Pro Lys Lys Ser Asn Glu Leu 1 5 10 15 Pro Gin Ala Asn Arg Leu Pro Gly Ile Phe Asp Asp Val His Gly Ser 20 25 30 His Gly Arg Gin Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Gin 35 40 45 Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gin Gly Tyr Ser Ala 50 55 60 Tyr Tyr Cys Glu Gly Glu Cys Ser Phe Pro Leu Asp Ser Cys Met Asn 65 70 75 80 Ala Thr Asn His Ala Ile Leu Gin Ser Leu Val His Leu Met Lys Pro 85 90 95 Asn Ala Val Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr 100 105 110 Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val Ile Leu Arg Lys His 115 120 125 Arg Asn Met Val Val Lys Ala Cys Gly Cys His 130 135 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 139 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear Ui) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: MURIDAE (F) TISSUE TYPE: EMBRYO (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..139 (D) OTHER INFORMATION: /label= MOP2-MATURE (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Ala Ala Arg Pro Leu Lys Arg Arg Gin Pro Lys Lys Thr Asn Glu Leu 1 5 10 15 Pro His Pro Asn Lys Leu Pro Gly Ile Phe Asp Asp Gly His Gly Ser 20 25 30 Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Arg 35 40 45 Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gin Gly Tyr Ser Ala 50 55 60 Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp Ser Cys Met Asn 65 70 75 80 Ala Thr Asn His Ala Ile Leu Gin Ser Leu Val His Leu Met Lys Pro 85 90 95 Asp Val Val Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr 100 105 110 Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val Ile Leu Arg Lys His 115 120 125 Arg Asn Met Val Val Lys Ala Cys Gly Cys His 130 135 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 101 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: bovinae (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..101 (D) OTHER INFORMATION: /label= CBMP-2A-FX (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Cys Lys Arg His Pro Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn 1 5 10 15 Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala Phe Tyr Cys His Gly 20 25 30 Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala 35 40 45 Ile Val Gin Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys Ala 50 55 60 Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp 65 70 75 80 Glu Asn Glu Lys Val Val Leu Lys Asn Tyr Gin Asp Met Val Val Glu 85 90 95 Gly Cys Gly Cys Arg 100 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 101 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: HOMO SAPIENS (F) TISSUE TYPE: hippocampus (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..101 (D) OTHER INFORMATION: /label- CBMP-2B-FX (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn 1 5 10 15 Asp Trp Ile Val Ala Pro Pro Gly Tyr Gin Ala Phe Tyr Cys His Gly 20 25 30 Asp Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala 35 40 45 Ile Val Gin Thr Leu Val Asn Ser Val Asn Ser Ser Ile Pro Lys Ala 50 55 60 Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp 65 70 75 80 Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gin Glu Met Val Val Glu 85 90 95 Gly Cys Gly Cys Arg 100 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: DROSOPHILA MELANOGASTER (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..101 (D) OTHER INFORMATION: /label= DPP-FX (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asp 1 5 10 15 Asp Trp Ile Val Ala Pro Leu Gly Tyr Asp Ala Tyr Tyr Cys His Gly 20 25 30 Lys Cys Pro Phe Pro Leu Ala Asp His Phe Asn Ser Thr Asn His Ala 35 40 45 Val Val Gin Thr Leu Val Asn Asn Asn Asn Pro Gly Lys Val Pro Lys 50 55 60 Ala Cys Cys Val Pro Thr Gin Leu Asp Ser Val Ala Met Leu Tyr Leu 65 70 75 80 Asn Asp Gin Ser Thr Val Val Leu Lys Asn Tyr Gin Glu Met Thr Val 85 90 95 Val Gly Cys Gly Cys Arg 100 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: XENOPUS (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..102 (D) OTHER INFORMATION: /label= VGL-FX (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys Asp Val Gly Trp Gin 1 5 10 15 Asn Trp Val Ile Ala Pro Gin Gly Tyr Met Ala Asn Tyr Cys Tyr Gly 20 25 30 Glu Cys Pro Tyr Pro Leu Thr Glu Ile Leu Asn Gly Ser Asn His Ala 35 40 45 Ile Leu Gin Thr Leu Val His Ser Ile Glu Pro Glu Asp Ile Pro Leu 50 55 60 Pro Cys Cys Val Pro Thr Lys Met Ser Pro Ile Ser Met Leu Phe Tyr 65 70 75 80 Asp Asn Asn Asp Asn Val Val Leu Arg His Tyr Glu Asn Met Ala Val 85 90 95 Asp Glu Cys Gly Cys Arg 100 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: MURIDAE (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..102 (D) OTHER INFORMATION: /label= VGR-l-FX (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Cys Lys Lys His Glu Leu Tyr Val Ser Phe Gin Asp Val Gly Trp Gin 1 5 10 15 Asp Trp Ile Ile Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly 20 25 30 Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala 35 40 45 lie Val Gin Thr Leu Val His Val Met Asn Pro Glu Tyr Val Pro Lys 50 55 60 Pro Cys Cys Ala Pro Thr Lys Val Asn Ala Ile Ser Val Leu Tyr Phe 65 70 75 80 Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val 85 90 95 Arg Ala Cys Gly Cys His 100 (2) INFORMATION FOR SEQ ID NO:13: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 106 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (m) HYPOTHETICAL: NO (iv) ANTI-SENSE. NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (F) TISSUE TYPE: brain (ix) FEATURE: (A) NAME/KEY. Protein (B) LOCATION: 1..106 (D) OTHER INFORMATION: /note= "GDF-1 (fx)" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: Cys Arg Ala Arg Arg Leu Tyr Val Ser Phe Arg Glu Val Gly Trp His 1 5 10 15 Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn Tyr Cys Gin Gly 20 25 30 Gin Cys Ala Leu Pro Val Ala Leu Ser Gly Ser Gly Gly Pro Pro Ala 35 40 45 Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala Ala Ala Pro Gly 50 55 60 Ala Ala Asp Leu Pro Cys Cys Val Pro Ala Arg Leu Ser Pro Ile Ser 65 70 75 80 Val Leu Phe Phe Asp Asn Ser Asp Asn Val Val Leu Arg Gin Tyr Glu 85 90 95 Asp Met Val Val Asp Glu Cys Gly Cys Arg 100 105 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Cys Xaa Xaa Xaa Xaa 1 5 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1822 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: HOMO SAPIENS (F) TISSUE TYPE: HIPPOCAMPUS (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 49..1341 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /function- "OSTEOGENIC PROTEIN" /product- "OPI" /evidence- EXPERIMENTAL /standard name- "OPI" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: GGTGCGGGCC CGGAGCCCGG AGCCCGGGTA GCGCGTAGAG CCGGCGCG ATG CAC GTG 57 Met His Val 1 CGC TCA CTG CGA GCT GCG GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA 105 Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala 5 10 15 CCC CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC AGC CTG GAC AAC 153 Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn 20 25 30 35 GAG GTG CAC TCG AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG 201 Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gin Glu Arg 40 45 50 CGG GAG ATG CAG CGC GAG ATC CTC TCC ATT TTG GGC TTG CCC CAC CGC 249 Arg Glu Met Gin Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg 55 60 65 CCG CGC CCG CAC CTC CAG GGC AAG CAC AAC TCG GCA CCC ATG TTC ATG 297 Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro Met Phe Met 70 75 80 CTG GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG GGC GGC GGG CCC GGC 345 Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Gly Pro Gly 85 90 95 GGC CAG GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC 393 Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gin Gly 100 105 110 115 CCC CCT CTG GCC AGC CTG CAA GAT AGC CAT TTC CTC ACC GAC GCC GAC 441 Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp Ala Asp 120 125 130 ATG GTC ATG AGC TTC GTC AAC CTC GTG GAA CAT GAC AAG GAA TTC TTC 489 Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe 135 140 145 CAC CCA CGC TAC CAC CAT CGA GAG TTC CGG TTT GAT CTT TCC AAG ATC 537 His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile 150 155 160 CCA GAA GGG GAA GCT GTC ACG GCA GCC GAA TTC CGG ATC TAC AAG GAC 585 Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp 165 170 175 TAC ATC CGG GAA CGC TTC GAC AAT GAG ACG TTC CGG ATC AGC GTT TAT 633 Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile Ser Val Tyr 180 185 190 195 CAG GTG CTC CAG GAG CAC TTG GGC AGG GAA TCG GAT CTC TTC CTG CTC 681 Gin Val Leu Gin Glu His Leu Gly Arg Glu Ser Asp Leu Phe Leu Leu 200 205 210 GAC AGC CGT ACC CTC TGG GCC TCG GAG GAG GGC TGG CTG GTG TTT GAC 729 Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp 215 220 225 ATC ACA GCC ACC AGC AAC CAC TGG GTG GTC AAT CCG CGG CAC AAC CTG 777 Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu 230 235 240 GGC CTG CAG CTC TCG GTG GAG ACG CTG GAT GGG CAG AGC ATC AAC CCC 825 Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser Ile Asn Pro 245 250 255 AAG TTG GCG GGC CTG ATT GGG CGG CAC GGG CCC CAG AAC AAG CAG CCC 873 Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gin Asn Lys Gin Pro 260 265 270 275 TTC ATG GTG GCT TTC TTC AAG GCC ACG GAG GTC CAC TTC CGC AGC ATC 921 Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe Arg Ser Ile 280 285 290 CGG TCC ACG GGG AGC AAA CAG CGC AGC CAG AAC CGC TCC AAG ACG CCC 969 Arg Ser Thr Gly Ser Lys Gin Arg Ser Gin Asn Arg Ser Lys Thr Pro 295 300 305 AAG AAC CAG GAA GCC CTG CGG ATG GCC AAC GTG GCA GAG AAC AGC AGC 1017 Lys Asn Gin Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser 310 315 320 AGC GAC CAG AGG CAG GCC TGT AAG AAG CAC GAG CTG TAT GTC AGC TTC 1065 Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe 325 330 335 CGA GAC CTG GGC TGG CAG GAC TGG ATC ATC GCG CCT GAA GGC TAC GCC 1113 Arg Asp Leu Gly Trp Gin Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala 340 345 350 355 GCC TAC TAC TGT GAG GGG GAG TGT GCC TTC CCT CTG AAC TCC TAC ATG 1161 Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met 360 365 370 AAC GCC ACC AAC CAC GCC ATC GTG CAG ACG CTG GTC CAC TTC ATC AAC 1209 Asn Ala Thr Asn His Ala Ile Val Gin Thr Leu Val His Phe Ile Asn 375 380 385 CCG GAA ACG GTG CCC AAG CCC TGC TGT GCG CCC ACG CAG CTC AAT GCC 1257 Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu Asn Ala 390 395 400 ATC TCC GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC CTG AAG AAA 1305 Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys 405 410 415 TAC AGA AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCCTCC 1351 Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430 GAGAATTCAG ACCCTTTGGG GCCAAGTTTT TCTGGATCCT CCATTGCTCG CCTTGGCCAG 1411 GAACCAGCAG ACCAACTGCC TTTTGTGAGA CCTTCCCCTC CCTATCCCCA ACTTTAAAGG 1471 TGTGAGAGTA TTAGGAAACA TGAGCAGCAT ATGGCTTTTG ATCAGTTTTT CAGTGGCAGC 1531 ATCCAATGAA CAAGATCCTA CAAGCTGTGC AGGCAAAACC TAGCAGGAAA AAAAAACAAC 1591 GCATAAAGAA AAATGGCCGG GCCAGGTCAT TGGCTGGGAA GTCTCAGCCA TGCACGGACT 1651 CGTTTCCAGA GGTAATTATG AGCGCCTACC AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG 1711 GGCGTGGCAA GGGGTGGGCA CATTGGTGTC TGTGCGAAAG GAAAATTGAC CCGGAAGTTC 1771 CTGTAATAAA TGTCACAATA AAACGAATGA ATGAAAAAAA AAAAAAAAAA A 1822 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 431 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala 1 5 10 15 Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser 20 25 30 Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser 35 40 45 Gin Glu Arg Arg Glu Met Gin Arg Glu Ile Leu Ser Ile Leu Gly Leu 50 55 60 Pro His Arg Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro 65 70 75 80 Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly 85 90 95 Gly Pro Gly Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser 100 105 110 Thr Gin Gly Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr 115 120 125 Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys 130 135 140 Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu 145 150 155 160 Ser Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile 165 170 175 Tyr Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile 180 185 190 Ser Val Tyr Gin Val Leu Gin Glu His Leu Gly Arg Glu Ser Asp Leu 195 200 205 - 56 - Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu 210 215 220 Val Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg 225 230 235 240 His Asn Leu Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser 245 250 255 Ile Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gin Asn 260 265 270 Lys Gin Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe 275 280 285 Arg Ser Ile Arg Ser Thr Gly Ser Lys Gin Arg Ser Gin Asn Arg Ser 290 295 300 Lys Thr Pro Lys Asn Gin Glu Ala Leu Arg Met Ala Asn Val Ala Glu 305 310 315 320 Asn Ser Ser Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr 325 330 335 Val Ser Phe Arg Asp Leu Gly Trp Gin Asp Trp Ile Ile Ala Pro Glu 340 345 350 Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn 355 360 365 Ser Tyr Met Asn Ala Thr Asn His Ala Ile Val Gin Thr Leu Val His 370 375 380 Phe Ile Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin 385 390 395 400 Leu Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile 405 410 415 Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1873 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: MURIDAE (F) TISSUE TYPE: EMBRYO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 104..1393 (D) OTHER INFORMATION: /function- "OSTEOGENIC PROTEIN" /product- "MOP1" /note- "MOP1 (CDNA) " (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: CTGCAGCAAG TGACCTCGGG TCGTGGACCG CTGCCCTGCC CCCTCCGCTG CCACCTGGGG 60 CGGCGCGGGC CCGGTGCCCC GGATCGCGCG TAGAGCCGGC GCG ATG CAC GTG CGC 115 Met His Val Arg 1 TCG CTG CGC GCT GCG GCG CCA CAC AGC TTC GTG GCG CTC TGG GCG CCT 163 Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala Pro 5 10 15 20 CTG TTC TTG CTG CGC TCC GCC CTG GCC GAT TTC AGC CTG GAC AAC GAG 211 Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn Glu 25 30 35 GTG CAC TCC AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG CGG 259 Val His Ser Ser Phe lie His Arg Arg Leu Arg Ser Gin Glu Arg Arg 40 45 50 GAG ATG CAG CGG GAG ATC CTG TCC ATC TTA GGG TTG CCC CAT CGC CCG 307 Glu Met Gin Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg Pro 55 60 65 CGC CCG CAC CTC CAG GGA AAG CAT AAT TCG GCG CCC ATG TTC ATG TTG 355 Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro Met Phe Met Leu 70 75 80 GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG AGC GGG CCG GAC GGA CAG 403 Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly Pro Asp Gly Gin 85 90 95 100 GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC CCC CCT 451 Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gin Gly Pro Pro 105 110 115 TTA GCC AGC CTG CAG GAC AGC CAT TTC CTC ACT GAC GCC GAC ATG GTC 499 Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp Ala Asp Met Val 120 125 130 ATG AGC TTC GTC AAC CTA GTG GAA CAT GAC AAA GAA TTC TTC CAC CCT 547 Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe His Pro 135 140 145 CGA TAC CAC CAT CGG GAG TTC CGG TTT GAT CTT TCC AAG ATC CCC GAG 595 - 58 - Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile Pro Glu 150 155 160 GGC GAA CGG GTG ACC GCA GCC GAA TTC AGG ATC TAT AAG GAC TAC ATC 643 Gly Glu Arg Val Thr Ala Ala Glu Phe Arg lie Tyr Lys Asp Tyr Ile 165 170 175 180 CGG GAG CGA TTT GAC AAC GAG ACC TTC CAG ATC ACA GTC TAT CAG GTG 691 Arg Glu Arg Phe Asp Asn Glu Thr Phe Gin Ile Thr Val Tyr Gin Val 185 190 195 CTC CAG GAG CAC TCA GGC AGG GAG TCG GAC CTC TTC TTG CTG GAC AGC 739 Leu Gin Glu His Ser Gly Arg Glu Ser Asp Leu Phe Leu Leu Asp Ser 200 205 210 CGC ACC ATC TGG GCT TCT GAG GAG GGC TGG TTG GTG TTT GAT ATC ACA 787 Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp Ile Thr 215 220 225 GCC ACC AGC AAC CAC TGG GTG GTC AAC CCT CGG CAC AAC CTG GGC TTA 835 Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu Gly Leu 230 235 240 CAG CTC TCT GTG GAG ACC CTG GAT GGG CAG AGC ATC AAC CCC AAG TTG 883 Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser Ile Asn Pro Lys Leu 245 250 255 260 GCA GGC CTG ATT GGA CGG CAT GGA CCC CAG AAC AAG CAA CCC TTC ATG 931 Ala Gly Leu Ile Gly Arg His Gly Pro Gin Asn Lys Gin Pro Phe Met 265 270 275 GTG GCC TTC TTC AAG GCC ACG GAA GTC CAT CTC CGT AGT ATC CGG TCC 979 Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg Ser Ile Arg Ser 280 285 290 ACG GGG GGC AAG CAG CGC AGC CAG AAT CGC TCC AAG ACG CCA AAG AAC 1027 Thr Gly Gly Lys Gin Arg Ser Gin Asn Arg Ser Lys Thr Pro Lys Asn 295 300 305 CAA GAG GCC CTG AGG ATG GCC AGT GTG GCA GAA AAC AGC AGC AGT GAC 1075 Gin Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn Ser Ser Ser Asp 310 315 320 CAG AGG CAG GCC TGC AAG AAA CAT GAG CTG TAC GTC AGC TTC CGA GAC 1123 Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp 325 330 335 340 CTT GGC TGG CAG GAC TGG ATC ATT GCA CCT GAA GGC TAT GCT GCC TAC 1171 Leu Gly Trp Gin Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr 345 350 355 TAC TGT GAG GGA GAG TGC GCC TTC CCT CTG AAC TCC TAC ATG AAC GCC 1219 Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala 360 365 370 ACC AAC CAC GCC ATC GTC CAG ACA CTG GTT CAC TTC ATC AAC CCA GAC 1267 Thr Asn His Ala Ile Val Gin Thr Leu Val His Phe Ile Asn Pro Asp 375 380 385 ACA GTA CCC AAG CCC TGC TGT GCG CCC ACC CAG CTC AAC GCC ATC TCT 1315 Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu Asn Ala Ile Ser 390 395 400 GTC CTC TAC TTC GAC GAC AGC TCT AAT GTC ATC CTG AAG AAG TAC AGA 1363 Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg 405 410 415 420 AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCTTCC TGAGACCCTG 1413 Asn Met Val Val Arg Ala Cys Gly Cys His 425 430 ACCTTTGCGG GGCCACACCT TTCCAAATCT TCGATGTCTC ACCATCTAAG TCTCTCACTG 1473 CCCACCTTGG CGAGGAGAAC AGACCAACCT CTCCTGAGCC TTCCCTCACC TCCCAACCGG 1533 AAGCATGTAA GGGTTCCAGA AACCTGAGCG TGCAGCAGCT GATGAGCGCC CTTTCCTTCT 1593 GGCACGTGAC GGACAAGATC CTACCAGCTA CCACAGCAAA CGCCTAAGAG CAGGAAAAAT 1653 GTCTGCCAGG AAAGTGTCCA GTGTCCACAT GGCCCCTGGC GCTCTGAGTC TTTGAGGAGT 1713 AATCGCAAGC CTCGTTCAGC TGCAGCAGAA GGAAGGGCTT AGCCAGGGTG GGCGCTGGCG 1773 TCTGTGTTGA AGGGAAACCA AGCAGAAGCC ACTGTAATGA TATGTCACAA TAAAACCCAT 1833 GAATGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAGAATTC 1873 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 430 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala 1 5 10 15 Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser 20 25 30 Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser 35 40 45 Gin Glu Arg Arg Glu Met Gin Arg Glu lie Leu Ser Ile Leu Gly Leu 50 55 60 Pro His Arg Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro 65 70 75 80 Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly 85 90 95 Pro Asp Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr 100 105 110 Gin Gly Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp 115 120 125 Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu 130 135 140 Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser 145 150 155 160 Lys lie Pro Glu Gly Glu Arg Val Thr Ala Ala Glu Phe Arg lie Tyr 165 170 175 Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Gin Ile Thr 180 185 190 Val Tyr Gin Val Leu Gin Glu His Ser Gly Arg Glu Ser Asp Leu Phe 195 200 205 Leu Leu Asp Ser Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val 210 215 220 Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His 225 230 235 240 Asn Leu Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser Ile 245 250 255 Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gin Asn Lys 260 265 270 Gin Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg 275 280 285 Ser Ile Arg Ser Thr Gly Gly Lys Gin Arg Ser Gin Asn Arg Ser Lys 290 295 300 Thr Pro Lys Asn Gin Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn 305 310 315 320 Ser Ser Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val 325 330 335 Ser Phe Arg Asp Leu Gly Trp Gin Asp Trp Ile Ile Ala Pro Glu Gly 340 345 350 Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser 355 360 365 Tyr Met Asn Ala Thr Asn His Ala Ile Val Gin Thr Leu Val His Phe 370 375 380 lie Asn Pro Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu 385 390 395 400 Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu 405 410 415 Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1723 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (F) TISSUE TYPE: HIPPOCAMPUS (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 490..1696 (D) OTHER INFORMATION: /function- "OSTEOGENIC PROTEIN" /product- "hOP2-PP" /note- "hOP2 (cDNA) " (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: GGCGCCGGCA GAGCAGGAGT GGCTGGAGGA GCTGTGGTTG GAGCAGGAGG TGGCACGGCA 60 GGGCTGGAGG GCTCCCTATG AGTGGCGGAG ACGGCCCAGG AGGCGCTGGA GCAACAGCTC 120 CCACACCGCA CCAAGCGGTG GCTGCAGGAG CTCGCCCATC GCCCCTGCGC TGCTCGGACC 180 GCGGCCACAG CCGGACTGGC GGGTACGGCG GCGACAGAGG CATTGGCCGA GAGTCCCAGT 240 CCGCAGAGTA GCCCCGGCCT CGAGGCGGTG GCGTCCCGGT CCTCTCCGTC CAGGAGCCAG 300 GACAGGTGTC GCGCGGCGGG GCTCCAGGGA CCGCGCCTGA GGCCGGCTGC CCGCCCGTCC 360 CGCCCCGCCC CGCCGCCCGC CGCCCGCCGA GCCCAGCCTC CTTGCCGTCG GGGCGTCCCC 420 AGGCCCTGGG TCGGCCGCGG AGCCGATGCG CGCCCGCTGA GCGCCCCAGC TGAGCGCCCC 480 CGGCCTGCC ATG ACC GCG CTC CCC GGC CCG CTC TGG CTC CTG GGC CTG 528 Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu 1 5 10 GCG CTA TGC GCG CTG GGC GGG GGC GGC CCC GGC CTG CGA CCC CCG CCC 576 Ala Leu Cys Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro 15 20 25 GGC TGT CCC CAG CGA CGT CTG GGC GCG CGC GAG CGC CGG GAC GTG CAG 624 Gly Cys Pro Gin Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gin 30 35 40 45 CGC GAG ATC CTG GCG GTG CTC GGG CTG CCT GGG CGG CCC CGG CCC CGC 672 Arg Glu Ile Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg 50 55 60 GCG CCA CCC GCC GCC TCC CGG CTG CCC GCG TCC GCG CCG CTC TTC ATG 720 Ala Pro Pro Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met 65 70 75 CTG GAC CTG TAC CAC GCC ATG GCC GGC GAC GAC GAC GAG GAC GGC GCG 768 Leu Asp Leu Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala 80 85 90 CCC GCG GAG CGG CGC CTG GGC CGC GCC GAC CTG GTC ATG AGC TTC GTT 816 Pro Ala Glu Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val 95 100 105 AAC ATG GTG GAG CGA GAC CGT GCC CTG GGC CAC CAG GAG CCC CAT TGG 864 Asn Met Val Glu Arg Asp Arg Ala Leu Gly His Gin Glu Pro His Trp 110 115 120 125 AAG GAG TTC CGC TTT GAC CTG ACC CAG ATC CCG GCT GGG GAG GCG GTC 912 Lys Glu Phe Arg Phe Asp Leu Thr Gin Ile Pro Ala Gly Glu Ala Val 130 135 140 ACA GCT GCG GAG TTC CGG ATT TAC AAG GTG CCC AGC ATC CAC CTG CTC 960 Thr Ala Ala Glu Phe Arg Ile Tyr Lys Val Pro Ser Ile His Leu Leu 145 150 155 AAC AGG ACC CTC CAC GTC AGC ATG TTC CAG GTG GTC CAG GAG CAG TCC 1008 Asn Arg Thr Leu His Val Ser Met Phe Gin Val Val Gin Glu Gin Ser 160 165 170 AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG CTC CGA GCT 1056 Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr Leu Arg Ala 175 180 185 GGA GAC GAG GGC TGG CTG GTG CTG GAT GTC ACA GCA GCC AGT GAC TGC 1104 Gly Asp Glu Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys 190 195 200 205 TGG TTG CTG AAG CGT CAC AAG GAC CTG GGA CTC CGC CTC TAT GTG GAG 1152 Trp Leu Leu Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu 210 215 220 ACT GAG GAC GGG CAC AGC GTG GAT CCT GGC CTG GCC GGC CTG CTG GGT 1200 Thr Glu Asp Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly 225 230 235 CAA CGG GCC CCA CGC TCC CAA CAG CCT TTC GTG GTC ACT TTC TTC AGG 1248 Gin Arg Ala Pro Arg Ser Gin Gin Pro Phe Val Val Thr Phe Phe Arg 240 245 250 GCC AGT CCG AGT CCC ATC CGC ACC CCT CGG GCA GTG AGG CCA CTG AGG 1296 Ala Ser Pro Ser Pro Ile Arg Thr Pro Arg Ala Val Arg Pro Leu Arg 255 260 265 AGG AGG CAG CCG AAG AAA AGC AAC GAG CTG CCG CAG GCC AAC CGA CTC 1344 Arg Arg Gin Pro Lys Lys Ser Asn Glu Leu Pro Gin Ala Asn Arg Leu 270 275 280 285 CCA GGG ATC TTT GAT GAC GTC CAC GGC TCC CAC GGC CGG CAG GTC TGC 1392 Pro Gly Ile Phe Asp Asp Val His Gly Ser His Gly Arg Gin Val Cys 290 295 300 CGT CGG CAC GAG CTC TAC GTC AGC TTC CAG GAC CTC GGC TGG CTG GAC 1440 Arg Arg His Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Leu Asp 305 310 315 TGG GTC ATC GCT CCC CAA GGC TAC TCG GCC TAT TAC TGT GAG GGG GAG 1488 Trp Val Ile Ala Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu 320 325 330 TGC TCC TTC CCA CTG GAC TCC TGC ATG AAT GCC ACC AAC CAC GCC ATC 1536 Cys Ser Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala Ile 335 340 345 CTG CAG TCC CTG GTG CAC CTG ATG AAG CCA AAC GCA GTC CCC AAG GCG 1584 Leu Gin Ser Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala 350 355 360 365 TGC TGT GCA CCC ACC AAG CTG AGC GCC ACC TCT GTG CTC TAC TAT GAC 1632 Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp 370 375 380 AGC AGC AAC AAC GTC ATC CTG CGC AAA CAC CGC AAC ATG GTG GTC AAG 1680 Ser Ser Asn Asn Val Ile Leu Arg Lys His Arg Asn Met Val Val Lys 385 390 395 GCC TGC GGC TGC CAC T GAGTCAGCCC GCCCAGCCCT ACTGCAG 1723 Ala Cys Gly Cys His 400 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15 Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro Gly Cys Pro 20 25 30 Gln Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gin Arg Glu Ile 35 40 45 Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Pro Pro 50 55 60 Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu 65 70 75 80 Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala Pro Ala Glu 85 90 95 Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val Asn Met Val 100 105 110 Glu Arg Asp Arg Ala Leu Gly His Gin Glu Pro His Trp Lys Glu Phe 115 120 125 Arg Phe Asp Leu Thr Gin Ile Pro Ala Gly Glu Ala Val Thr Ala Ala 130 135 140 Glu Phe Arg Ile Tyr Lys Val Pro Ser Ile His Leu Leu Asn Arg Thr 145 150 155 160 Leu His Val Ser Met Phe Gin Val Val Gin Glu Gin Ser Asn Arg Glu 165 170 175 Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr Leu Arg Ala Gly Asp Glu 180 185 190 Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys Trp Leu Leu 195 200 205 Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Glu Asp 210 215 220 Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly Gin Arg Ala 225 230 235 240 Pro Arg Ser Gin Gin Pro Phe Val Val Thr Phe Phe Arg Ala Ser Pro 245 250 255 Ser Pro Ile Arg Thr Pro Arg Ala Val Arg Pro Leu Arg Arg Arg Gin 260 265 270 Pro Lys Lys Ser Asn Glu Leu Pro Gin Ala Asn Arg Leu Pro Gly Ile 275 280 285 Phe Asp Asp Val His Gly Ser His Gly Arg Gin Val Cys Arg Arg His 290 295 300 Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Leu Asp Trp Val Ile 305 310 315 320 Ala Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ser Phe 325 330 335 Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala Ile Leu Gin Ser 340 345 350 Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala Cys Cys Ala 355 360 365 Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn 370 375 380 Asn Val Ile Leu Arg Lys His Arg Asn Met Val Val Lys Ala Cys Gly 385 390 395 400 Cys His (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1926 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE: (A) ORGANISM: MURIDAE (F) TISSUE TYPE: EMBRYO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 93..1289 (D) OTHER INFORMATION: /function- "OSTEOGENIC PROTEIN" /product- "mOP2-PP" /note- "mOP2 cDNA" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: GCCAGGCACA GGTGCGCCGT CTGGTCCTCC CCGTCTGGCG TCAGCCGAGC CCGACCAGCT 60 ACCAGTGGAT GCGCGCCGGC TGAAAGTCCG AG ATG GCT ATG CGT CCC GGG CCA 113 Met Ala Met Arg Pro Gly Pro 1 5 CTC TGG CTA TTG GGC CTT GCT CTG TGC GCG CTG GGA GGC GGC CAC GGT 161 Leu Trp Leu Leu Gly Leu Ala Leu Cys Ala Leu Gly Gly Gly His Gly 10 15 20 CCG CGT CCC CCG CAC ACC TGT CCC CAG CGT CGC CTG GGA GCG CGC GAG 209 Pro Arg Pro Pro His Thr Cys Pro Gin Arg Arg Leu Gly Ala Arg Glu 25 30 35 CGC CGC GAC ATG CAG CGT GAA ATC CTG GCG GTG CTC GGG CTA CCG GGA 257 Arg Arg Asp Met Gin Arg Glu Ile Leu Ala Val Leu Gly Leu Pro Gly 40 45 50 55 CGG CCC CGA CCC CGT GCA CAA CCC GCC GCT GCC CGG CAG CCA GCG TCC 305 Arg Pro Arg Pro Arg Ala Gin Pro Ala Ala Ala Arg Gin Pro Ala Ser 60 65 70 GCG CCC CTC TTC ATG TTG GAC CTA TAC CAC GCC ATG ACC GAT GAC GAC 353 Ala Pro Leu Phe Met Leu Asp Leu Tyr His Ala Met Thr Asp Asp Asp 75 80 85 GAC GGC GGG CCA CCA CAG GCT CAC TTA GGC CGT GCC GAC CTG GTC ATG 401 Asp Gly Gly Pro Pro Gin Ala His Leu Gly Arg Ala Asp Leu Val Met 90 95 100 AGC TTC GTC AAC ATG GTG GAA CGC GAC CGT ACC CTG GGC TAC CAG GAG 449 Ser Phe Val Asn Met Val Glu Arg Asp Arg Thr Leu Gly Tyr Gin Glu 105 110 115 CCA CAC TGG AAG GAA TTC CAC TTT GAC CTA ACC CAG ATC CCT GCT GGG 497 Pro His Trp Lys Glu Phe His Phe Asp Leu Thr Gin Ile Pro Ala Gly 120 125 130 135 GAG GCT GTC ACA GCT GCT GAG TTC CGG ATC TAC AAA GAA CCC AGC ACC 545 Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Glu Pro Ser Thr 140 145 150 CAC CCG CTC AAC ACA ACC CTC CAC ATC AGC ATG TTC GAA GTG GTC CAA 593 His Pro Leu Asn Thr Thr Leu His lie Ser Met Phe Glu Val Val Gin 155 160 165 GAG CAC TCC AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG 641 Glu His Ser Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr 170 175 180 CTC CGA TCT GGG GAC GAG GGC TGG CTG GTG CTG GAC ATC ACA GCA GCC 689 Leu Arg Ser Gly Asp Glu Gly Trp Leu Val Leu Asp Ile Thr Ala Ala 185 190 195 AGT GAC CGA TGG CTG CTG AAC CAT CAC AAG GAC CTG GGA CTC CGC CTC 737 Ser Asp Arg Trp Leu Leu Asn His His Lys Asp Leu Gly Leu Arg Leu 200 205 210 215 TAT GTG GAA ACC GCG GAT GGG CAC AGC ATG GAT CCT GGC CTG GCT GGT 785 Tyr Val Glu Thr Ala Asp Gly His Ser Met Asp Pro Gly Leu Ala Gly 220 225 230 CTG CTT GGA CGA CAA GCA CCA CGC TCC AGA CAG CCT TTC ATG GTA ACC 833 Leu Leu Gly Arg Gin Ala Pro Arg Ser Arg Gin Pro Phe Met Val Thr 235 240 245 TTC TTC AGG GCC AGC CAG AGT CCT GTG CGG GCC CCT CGG GCA GCG AGA 881 Phe Phe Arg Ala Ser Gin Ser Pro Val Arg Ala Pro Arg Ala Ala Arg 250 255 260 CCA CTG AAG AGG AGG CAG CCA AAG AAA ACG AAC GAG CTT CCG CAC CCC 929 Pro Leu Lys Arg Arg Gin Pro Lys Lys Thr Asn Glu Leu Pro His Pro 265 270 275 AAC AAA CTC CCA GGG ATC TTT GAT GAT GGC CAC GGT TCC CGC GGC AGA 977 Asn Lys Leu Pro Gly Ile Phe Asp Asp Gly His Gly Ser Arg Gly Arg 280 285 290 295 GAG GTT TGC CGC AGG CAT GAG CTC TAC GTC AGC TTC CGT GAC CTT GGC 1025 Glu Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly 300 305 310 TGG CTG GAC TGG GTC ATC GCC CCC CAG GGC TAC TCT GCC TAT TAC TGT 1073 Trp Leu Asp Trp Val Ile Ala Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys 315 320 325 GAG GGG GAG TGT GCT TTC CCA CTG GAC TCC TGT ATG AAC GCC ACC AAC 1121 Glu Gly Glu Cys Ala Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn 330 335 340 CAT GCC ATC TTG CAG TCT CTG GTG CAC CTG ATG AAG CCA GAT GTT GTC 1169 His Ala Ile Leu Gin Ser Leu Val His Leu Met Lys Pro Asp Val Val 345 350 355 CCC AAG GCA TGC TGT GCA CCC ACC AAA CTG AGT GCC ACC TCT GTG CTG 1217 Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu 360 365 370 375 TAC TAT GAC AGC AGC AAC AAT GTC ATC CTG CGT AAA CAC CGT AAC ATG 1265 Tyr Tyr Asp Ser Ser Asn Asn Val Ile Leu Arg Lys His Arg Asn Met 380 385 390 GTG GTC AAG GCC TGT GGC TGC CAC TGAGGCCCCG CCCAGCATCC TGCTTCTACT 1319 Val Val Lys Ala Cys Gly Cys His 395 ACCTTACCAT CTGGCCGGGC CCCTCTCCAG AGGCAGAAAC CCTTCTATGT TATCATAGCT 1379 CAGACAGGGG CAATGGGAGG CCCTTCACTT CCCCTGGCCA CTTCCTGCTA AAATTCTGGT 1439 CTTTCCCAGT TCCTCTGTCC TTCATGGGGT TTCGGGGCTA TCACCCCGCC CTCTCCATCC 1499 TCCTACCCCA AGCATAGACT GAATGCACAC AGCATCCCAG AGCTATGCTA ACTGAGAGGT 1559 CTGGGGTCAG CACTGAAGGC CCACATGAGG AAGACTGATC CTTGGCCATC CTCAGCCCAC 1619 AATGGCAAAT TCTGGATGGT CTAAGAAGGC CCTGGAATTC TAAACTAGAT GATCTGGGCT 1679 CTCTGCACCA TTCATTGTGG CAGTTGGGAC ATTTTTAGGT ATAACAGACA CATACACTTA 1739 GATCAATGCA TCGCTGTACT CCTTGAAATC AGAGCTAGCT TGTTAGAAAA AGAATCAGAG 1799 CCAGGTATAG CGGTGCATGT CATTAATCCC AGCGCTAAAG AGACAGAGAC AGGAGAATCT 1859 CTGTGAGTTC AAGGCCACAT AGAAAGAGCC TGTCTCGGGA GCAGGAAAAA AAAAAAAAAC 1919 GGAATTC 1926 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Met Ala Met Arg Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15 Ala Leu Gly Gly Gly His Gly Pro Arg Pro Pro His Thr Cys Pro Gin 20 25 30 Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Met Gin Arg Glu Ile Leu 35 40 45 Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Gin Pro Ala 50 55 60 Ala Ala Arg Gin Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr 65 70 75 80 His Ala Met Thr Asp Asp Asp Asp Gly Gly Pro Pro Gin Ala His Leu 85 90 95 Gly Arg Ala Asp Leu Val Met Ser Phe Val Asn Met Val Glu Arg Asp 100 105 110 Arg Thr Leu Gly Tyr Gin Glu Pro His Trp Lys Glu Phe His Phe Asp 115 120 125 Leu Thr Gin Ile Pro Ala Gly Glu Ala Val Thr Ala Ala Glu Phe Arg 130 135 140 Ile Tyr Lys Glu Pro Ser Thr His Pro Leu Asn Thr Thr Leu His Ile 145 150 155 160 Ser Met Phe Glu Val Val Gin Glu His Ser Asn Arg Glu Ser Asp Leu 165 170 175 Phe Phe Leu Asp Leu Gin Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu 180 185 190 Val Leu Asp Ile Thr Ala Ala Ser Asp Arg Trp Leu Leu Asn His His 195 200 205 Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Ala Asp Gly His Ser 210 215 220 Met Asp Pro Gly Leu Ala Gly Leu Leu Gly Arg Gin Ala Pro Arg Ser 225 230 235 240 Arg Gin Pro Phe Met Val Thr Phe Phe Arg Ala Ser Gin Ser Pro Val 245 250 255 Arg Ala Pro Arg Ala Ala Arg Pro Leu Lys Arg Arg Gin Pro Lys Lys 260 265 270 Thr Asn Glu Leu Pro His Pro Asn Lys Leu Pro Gly Ile Phe Asp Asp 275 280 285 Gly His Gly Ser Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr 290 295 300 Val Ser Phe Arg Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gin 305 310 315 320 Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp 325 330 335 Ser Cys Met Asn Ala Thr Asn His Ala Ile Leu Gin Ser Leu Val His 340 345 350 Leu Met Lys Pro Asp Val Val Pro Lys Ala Cys Cys Ala Pro Thr Lys 355 360 365 Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val Ile 370 375 380 Leu Arg Lys His Arg Asn Met Val Val Lys Ala Cys Gly Cys His 385 390 395 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1368 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1368 (D) OTHER INFORMATION: /label- "60A" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: ATG TCG GGA CTG CGA AAC ACC TCG GAG GCC GTT GCA GTG CTC GCC TCC 48 Met Ser Gly Leu Arg Asn Thr Ser Glu Ala Val Ala Val Leu Ala Ser 1 5 10 15 CTG GGA CTC GGA ATG GTT CTG CTC ATG TTC GTG GCG ACC ACG CCG CCG 96 Leu Gly Leu Gly Met Val Leu Leu Met Phe Val Ala Thr Thr Pro Pro 20 25 30 GCC GTT GAG GCC ACC CAG TCG GGG ATT TAC ATA GAC AAC GGC AAG GAC 144 Ala Val Glu Ala Thr Gin Ser Gly Ile Tyr Ile Asp Asn Gly Lys Asp 35 40 45 CAG ACG ATC ATG CAC AGA GTG CTG AGC GAG GAC GAC AAG CTG GAC GTC 192 Gin Thr Ile Met His Arg Val Leu Ser Glu Asp Asp Lys Leu Asp Val 50 55 60 TCG TAC GAG ATC CTC GAG TTC CTG GGC ATC GCC GAA CGG CCG ACG CAC 240 Ser Tyr Glu Ile Leu Glu Phe Leu Gly Ile Ala Glu Arg Pro Thr His 65 70 75 80 CTG AGC AGC CAC CAG TTG TCG CTG AGG AAG TCG GCT CCC AAG TTC CTG 288 Leu Ser Ser His Gin Leu Ser Leu Arg Lys Ser Ala Pro Lys Phe Leu 85 90 95 CTG GAC GTC TAC CAC CGC ATC ACG GCG GAG GAG GGT CTC AGC GAT CAG 336 Leu Asp Val Tyr His Arg Ile Thr Ala Glu Glu Gly Leu Ser Asp Gin 100 105 110 GAT GAG GAC GAC GAC TAC GAA CGC GGC CAT CGG TCC AGG AGG AGC GCC 384 Asp Glu Asp Asp Asp Tyr Glu Arg Gly His Arg Ser Arg Arg Ser Ala 115 120 125 GAC CTC GAG GAG GAT GAG GGC GAG CAG CAG AAG AAC TTC ATC ACC GAC 432 Asp Leu Glu Glu Asp Glu Gly Glu Gin Gin Lys Asn Phe Ile Thr Asp 130 135 140 CTG GAC AAG CGG GCC ATC GAC GAG AGC GAC ATC ATC ATG ACC TTC CTG 480 Leu Asp Lys Arg Ala Ile Asp Glu Ser Asp Ile Ile Met Thr Phe Leu 145 150 155 160 AAC AAG CGC CAC CAC AAT GTG GAC GAA CTG CGT CAC GAG CAC GGC CGT 528 Asn Lys Arg His His Asn Val Asp Glu Leu Arg His Glu His Gly Arg 165 170 175 CGC CTG TGG TTC GAC GTC TCC AAC GTG CCC AAC GAC AAC TAC CTG GTG 576 Arg Leu Trp Phe Asp Val Ser Asn Val Pro Asn Asp Asn Tyr Leu Val 180 185 190 ATG GCC GAG CTG CGC ATC TAT CAG AAC GCC AAC GAG GGC AAG TGG CTG 624 Met Ala Glu Leu Arg Ile Tyr Gin Asn Ala Asn Glu Gly Lys Trp Leu 195 200 205 ACC GCC AAC AGG GAG TTC ACC ATC ACG GTA TAC GCC ATT GGC ACC GGC 672 Thr Ala Asn Arg Glu Phe Thr Ile Thr Val Tyr Ala Ile Gly Thr Gly 210 215 220 ACG CTG GGC CAG CAC ACC ATG GAG CCG CTG TCC TCG GTG AAC ACC ACC 720 Thr Leu Gly Gin His Thr Met Glu Pro Leu Ser Ser Val Asn Thr Thr 225 230 235 240 GGG GAC TAC GTG GGC TGG TTG GAG CTC AAC GTG ACC GAG GGC CTG CAC 768 Gly Asp Tyr Val Gly Trp Leu Glu Leu Asn Val Thr Glu Gly Leu His 245 250 255 GAG TGG CTG GTC AAG TCG AAG GAC AAT CAT GGC ATC TAC ATT GGA GCA 816 Glu Trp Leu Val Lys Ser Lys Asp Asn His Gly Ile Tyr Ile Gly Ala 260 265 270 CAC GCT GTC AAC CGA CCC GAC CGC GAG GTG AAG CTG GAC GAC ATT GGA 864 His Ala Val Asn Arg Pro Asp Arg Glu Val Lys Leu Asp Asp Ile Gly 275 280 285 CTG ATC CAC CGC AAG GTG GAC GAC GAG TTC CAG CCC TTC ATG ATC GGC 912 Leu Ile His Arg Lys Val Asp Asp Glu Phe Gin Pro Phe Met Ile Gly 290 295 300 TTC TTC CGC GGA CCG GAG CTG ATC AAG GCG ACG GCC CAC AGC AGC CAC 960 Phe Phe Arg Gly Pro Glu Leu Ile Lys Ala Thr Ala His Ser Ser His 305 310 315 320 CAC AGG AGC AAG CGA AGC GCC AGC CAT CCA CGC AAG CGC AAG AAG TCG 1008 His Arg Ser Lys Arg Ser Ala Ser His Pro Arg Lys Arg Lys Lys Ser 325 330 335 GTG TCG CCC AAC AAC GTG CCG CTG CTG GAA CCG ATG GAG AGC ACG CGC 1056 Val Ser Pro Asn Asn Val Pro Leu Leu Glu Pro Met Glu Ser Thr Arg 340 345 350 AGC TGC CAG ATG CAG ACC CTG TAC ATA GAC TTC AAG GAT CTG GGC TGG 1104 Ser Cys Gin Met Gin Thr Leu Tyr Ile Asp Phe Lys Asp Leu Gly Trp 355 360 365 CAT GAC TGG ATC ATC GCA CCA GAG GGC TAT GGC GCC TTC TAC TGC AGC 1152 His Asp Trp Ile Ile Ala Pro Glu Gly Tyr Gly Ala Phe Tyr Cys Ser 370 375 380 GGC GAG TGC AAT TTC CCG CTC AAT GCG CAC ATG AAC GCC ACG AAC CAT 1200 Gly Glu Cys Asn Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His 385 390 395 400 GCG ATC GTC CAG ACC CTG GTC CAC CTG CTG GAG CCC AAG AAG GTG CCC 1248 Ala Ile Val Gin Thr Leu Val His Leu Leu Glu Pro Lys Lys Val Pro 405 410 415 AAG CCC TGC TGC GCT CCG ACC AGG CTG GGA GCA CTA CCC GTT CTG TAC 1296 Lys Pro Cys Cys Ala Pro Thr Arg Leu Gly Ala Leu Pro Val Leu Tyr 420 425 430 CAC CTG AAC GAC GAG AAT GTG AAC CTG AAA AAG TAT AGA AAC ATG ATT 1344 His Leu Asn Asp Glu Asn Val Asn Leu Lys Lys Tyr Arg Asn Met Ile 435 440 445 GTG AAA TCC TGC GGG TGC CAT TGA 1368 Val Lys Ser Cys Gly Cys His 450 455 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 455 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24 Met Ser Gly Leu Arg Asn Thr Ser Glu Ala Val Ala Val Leu Ala Ser 1 5 10 15 Leu Gly Leu Gly Met Val Leu Leu Met Phe Val Ala Thr Thr Pro Pro 20 25 30 Ala Val Glu Ala Thr Gin Ser Gly Ile Tyr Ile Asp Asn Gly Lys Asp 35 40 45 Gin Thr Ile Met His Arg Val Leu Ser Glu Asp Asp Lys Leu Asp Val 50 55 60 Ser Tyr Glu Ile Leu Glu Phe Leu Gly Ile Ala Glu Arg Pro Thr His 65 70 75 80 Leu Ser Ser His Gin Leu Ser Leu Arg Lys Ser Ala Pro Lys Phe Leu 85 90 95 Leu Asp Val Tyr His Arg Ile Thr Ala Glu Glu Gly Leu Ser Asp Gin 100 105 110 Asp Glu Asp Asp Asp Tyr Glu Arg Gly His Arg Ser Arg Arg Ser Ala 115 120 125 Asp Leu Glu Glu Asp Glu Gly Glu Gin Gin Lys Asn Phe Ile Thr Asp 130 135 140 Leu Asp Lys Arg Ala Ile Asp Glu Ser Asp Ile Ile Met Thr Phe Leu 145 150 155 160 Asn Lys Arg His His Asn Val Asp Glu Leu Arg His Glu His Gly Arg 165 170 175 Arg Leu Trp Phe Asp Val Ser Asn Val Pro Asn Asp Asn Tyr Leu Val 180 185 190 Met Ala Glu Leu Arg Ile Tyr Gin Asn Ala Asn Glu Gly Lys Trp Leu 195 200 205 Thr Ala Asn Arg Glu Phe Thr Ile Thr Val Tyr Ala Ile Gly Thr Gly 210 215 220 Thr Leu Gly Gin His Thr Met Glu Pro Leu Ser Ser Val Asn Thr Thr 225 230 235 240 Gly Asp Tyr Val Gly Trp Leu Glu Leu Asn Val Thr Glu Gly Leu His 245 250 255 Glu Trp Leu Val Lys Ser Lys Asp Asn His Gly Ile Tyr Ile Gly Ala 260 265 270 His Ala Val Asn Arg Pro Asp Arg Glu Val Lys Leu Asp Asp Ile Gly 275 280 285 Leu Ile His Arg Lys Val Asp Asp Glu Phe Gin Pro Phe Met Ile Gly 290 295 300 Phe Phe Arg Gly Pro Glu Leu Ile Lys Ala Thr Ala His Ser Ser His 305 310 315 320 His Arg Ser Lys Arg Ser Ala Ser His Pro Arg Lys Arg Lys Lys Ser 325 330 335 Val Ser Pro Asn Asn Val Pro Leu Leu Glu Pro Met Glu Ser Thr Arg 340 345 350 Ser Cys Gin Met Gin Thr Leu Tyr Ile Asp Phe Lys Asp Leu Gly Trp 355 360 365 His Asp Trp Ile Ile Ala Pro Glu Gly Tyr Gly Ala Phe Tyr Cys Ser 370 375 380 Gly Glu Cys Asn Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His 385 390 395 400 Ala Ile Val Gin Thr Leu Val His Leu Leu Glu Pro Lys Lys Val Pro 405 410 415 Lys Pro Cys Cys Ala Pro Thr Arg Leu Gly Ala Leu Pro Val Leu Tyr 420 425 430 His Leu Asn Asp Glu Asn Val Asn Leu Lys Lys Tyr Arg Asn Met Ile 435 440 445 Val Lys Ser Cys Gly Cys His 450 455 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1674 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 69..1268 (D) OTHER INFORMATION: /note- "mOP3-PP" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GGATCCGCGG CGCTGTCCCA TCCTTGTCGT CGAGGCGTCG CTGGATGCGA GTCCGCTAAA 60 CGTCCGAG ATG GCT GCG CGT CCG GGA CTC CTA TGG CTA CTG GGC CTG GCT 110 Met Ala Ala Arg Pro Gly Leu Leu Trp Leu Leu Gly Leu Ala 1 5 10 CTG TGC GTG TTG GGC GGC GGT CAC CTC TCG CAT CCC CCG CAC GTC TTT 158 Leu Cys Val Leu Gly Gly Gly His Leu Ser His Pro Pro His Val Phe 15 20 25 30 CCC CAG CGT CGA CTA GGA GTA CGC GAG CCC CGC GAC ATG CAG CGC GAG 206 Pro Gin Arg Arg Leu Gly Val Arg Glu Pro Arg Asp Met Gin Arg Glu 35 40 45 ATT CGG GAG GTG CTG GGG CTA GCC GGG CGG CCC CGA TCC CGA GCA CCG 254 Ile Arg Glu Val Leu Gly Leu Ala Gly Arg Pro Arg Ser Arg Ala Pro 50 55 60 GTC GGG GCT GCC CAG CAG CCA GCG TCT GCG CCC CTC TTT ATG TTG GAC 302 Val Gly Ala Ala Gin Gin Pro Ala Ser Ala Pro Leu Phe Met Leu Asp 65 70 75 CTG TAC CGT GCC ATG ACG GAT GAC AGT GGC GGT GGG ACC CCG CAG CCT 350 Leu Tyr Arg Ala Met Thr Asp Asp Ser Gly Gly Gly Thr Pro Gin Pro 80 85 90 CAC TTG GAC CGT GCT GAC CTG ATT ATG AGC TTT GTC AAC ATA GTG GAA 398 His Leu Asp Arg Ala Asp Leu Ile Met Ser Phe Val Asn Ile Val Glu 95 100 105 110 CGC GAC CGT ACC CTG GGC TAC CAG GAG CCA CAC TGG AAG GAA TTC CAC 446 Arg Asp Arg Thr Leu Gly Tyr Gin Glu Pro His Trp Lys Glu Phe His 115 120 125 TTT GAC CTA ACC CAG ATC CCT GCT GGG GAG GCT GTC ACA GCT GCT GAG 494 Phe Asp Leu Thr Gin Ile Pro Ala Gly Glu Ala Val Thr Ala Ala Glu 130 135 140 TTC CGG ATC TAC AAA GAA CCC AGT ACC CAC CCG CTC AAC ACA ACC CTC 542 Phe Arg Ile Tyr Lys Glu Pro Ser Thr His Pro Leu Asn Thr Thr Leu 145 150 155 CAC ATC AGC ATG TTC GAA GTG GTC CAA GAG CAC TCC AAC AGG GAG TCT 590 His Ile Ser Met Phe Glu Val Val Gin Glu His Ser Asn Arg Glu Ser 160 165 170 GAC TTG TTC TTT TTG GAT CTT CAG ACG CTC CGA TCT GGG GAC GAG GGC 638 Asp Leu Phe Phe Leu Asp Leu Gin Thr Leu Arg Ser Gly Asp Glu Gly 175 180 185 190 TGG CTG GTG CTG GAC ATC ACA GCA GCC AGT GAC CGA TGG CTG CTG AAC 686 Trp Leu Val Leu Asp Ile Thr Ala Ala Ser Asp Arg Trp Leu Leu Asn 195 200 205 CAT CAC AAG GAC CTA GGA CTC CGC CTC TAT GTG GAA ACC GAG GAT GGG 734 His His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Glu Asp Gly 210 215 220 CAC AGC ATA GAT CCT GGC CTA GCT GGT CTG CTT GGA CGA CAA GCA CCA 782 His Ser Ile Asp Pro Gly Leu Ala Gly Leu Leu Gly Arg Gin Ala Pro 225 230 235 CGC TCC AGA CAG CCT TTC ATG GTT GGT TTC TTC AGG GCC AAC CAG AGT 830 Arg Ser Arg Gin Pro Phe Met Val Gly Phe Phe Arg Ala Asn Gin Ser 240 245 250 CCT GTG CGG GCC CCT CGA ACA GCA AGA CCA CTG AAG AAG AAG CAG CTA 878 Pro Val Arg Ala Pro Arg Thr Ala Arg Pro Leu Lys Lys Lys Gin Leu 255 260 265 270 AAT CAA ATC AAC CAG CTG CCG CAC TCC AAC AAA CAC CTA GGA ATC CTT 926 Asn Gin Ile Asn Gin Leu Pro His Ser Asn Lys His Leu Gly Ile Leu 275 280 285 GAT GAT GGC CAC GGT TCT CAC GGC AGA GAA GTT TGC CGC AGG CAT GAG 974 Asp Asp Gly His Gly Ser His Gly Arg Glu Val Cys Arg Arg His Glu 290 295 300 CTC TAT GTC AGC TTC CGT GAC CTT GGC TGG CTG GAC TCT GTC ATT GCC 1022 Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Leu Asp Ser Val Ile Ala 305 310 315 CCC CAG GGC TAC TCC GCC TAT TAC TGT GCT GGG GAG TGC ATC TAC CCA 1070 Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys Ala Gly Glu Cys Ile Tyr Pro 320 325 330 CTG AAC TCC TGT ATG AAC TCC ACC AAC CAC GCC ACT ATG CAG GCC CTG 1118 Leu Asn Ser Cys Met Asn Ser Thr Asn His Ala Thr Met Gin Ala Leu 335 340 345 350 GTA CAT CTG ATG AAG CCA GAT ATC ATC CCC AAG GTG TGC TGT GTG CCT 1166 Val His Leu Met Lys Pro Asp lie Ile Pro Lys Val Cys Cys Val Pro 355 360 365 ACT GAG CTG AGT GCC ATT TCT CTG CTC TAC TAT GAT AGA AAC AAT AAT 1214 Thr Glu Leu Ser Ala Ile Ser Leu Leu Tyr Tyr Asp Arg Asn Asn Asn 370 375 380 GTC ATC CTG CGC AGG GAG CGC AAC ATG GTA GTC CAG GCC TGT GGC TGC 1262 Val Ile Leu Arg Arg Glu Arg Asn Met Val Val Gin Ala Cys Gly Cys 385 390 395 CAC TGAGTCCCTG CCCAACAGCC TGCTGCCATC CCATCTATCT AGTCAGGCCT 1315 His 400 CTCTTCCAAG GCAGGAAACC AACAAAGAGG GAAGGCAGTG CTTTCAACTC CATGTCCACA 1375 TTCACAGTCT TGGCCCTCTC TGTTCTTTTT GCCAAGGCTG AGAAGATGGT CCTAGTTATA 1435 ACCCTGGTGA CCTCAGTAGC CCGATCTCTC ATCTCCCCAA ACTCCCCAAT GCAGCCAGGG 1495 GCATCTATGT CCTTTGGGAT TGGGCACAGA AGTCCAATTT ACCAACTTAT TCATGAGTCA 1555 CTACTGGCCC AGCCTGGACT TGAACCTGGA ACACAGGGTA GAGCTCAGGC TCTTCAGTAT 1615 CCATCAGAAG ATTTAGGTGT GTGCAGACAT GACCACACTC CCCCTAGCAC TCCATAGCC 1674 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Met Ala Ala Arg Pro Gly Leu Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15 Val Leu Gly Gly Gly His Leu Ser His Pro Pro His Val Phe Pro Gin 20 25 30 Arg Arg Leu Gly Val Arg Glu Pro Arg Asp Met Gin Arg Glu Ile Arg 35 40 45 Glu Val Leu Gly Leu Ala Gly Arg Pro Arg Ser Arg Ala Pro Val Gly 50 55 60 Ala Ala Gin Gin Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr 65 70 75 80 Arg Ala Met Thr Asp Asp Ser Gly Gly Gly Thr Pro Gin Pro His Leu 85 90 95 Asp Arg Ala Asp Leu Ile Met Ser Phe Val Asn Ile Val Glu Arg Asp 100 105 110 Arg Thr Leu Gly Tyr Gin Glu Pro His Trp Lys Glu Phe His Phe Asp 115 120 125 Leu Thr Gin Ile Pro Ala Gly Glu Ala Val Thr Ala Ala Glu Phe Arg 130 135 140 Ile Tyr Lys Glu Pro Ser Thr His Pro Leu Asn Thr Thr Leu His Ile 145 150 155 160 Ser Met Phe Glu Val Val Gin Glu His Ser Asn Arg Glu Ser Asp Leu 165 170 175 Phe Phe Leu Asp Leu Gin Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu 180 185 190 Val Leu Asp Ile Thr Ala Ala Ser Asp Arg Trp Leu Leu Asn His His 195 200 205 Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Glu Asp Gly His Ser 210 215 220 lie Asp Pro Gly Leu Ala Gly Leu Leu Gly Arg Gin Ala Pro Arg Ser 225 230 235 240 Arg Gin Pro Phe Met Val Gly Phe Phe Arg Ala Asn Gin Ser Pro Val 245 250 255 Arg Ala Pro Arg Thr Ala Arg Pro Leu Lys Lys Lys Gin Leu Asn Gin 260 265 270 Ile Asn Gin Leu Pro His Ser Asn Lys His Leu Gly Ile Leu Asp Asp 275 280 285 Gly His Gly Ser His Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr 290 295 300 Val Ser Phe Arg Asp Leu Gly Trp Leu Asp Ser Val Ile Ala Pro Gin 305 310 315 320 Gly Tyr Ser Ala Tyr Tyr Cys Ala Gly Glu Cys Ile Tyr Pro Leu Asn 325 330 335 Ser Cys Met Asn Ser Thr Asn His Ala Thr Met Gin Ala Leu Val His 340 345 350 Leu Met Lys Pro Asp Ile Ile Pro Lys Val Cys Cys Val Pro Thr Glu 355 360 365 Leu Ser Ala Ile Ser Leu Leu Tyr Tyr Asp Arg Asn Asn Asn Val Ile 370 375 380 Leu Arg Arg Glu Arg Asn Met Val Val Gin Ala Cys Gly Cys His 385 390 395 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 104 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..104 (D) OTHER INFORMATION: /note- "BMP3" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Cys Ala Arg Arg Tyr Leu Lys Val Asp Phe Ala Asp Ile Gly Trp Ser 1 5 10 15 Glu Trp Ile Ile Ser Pro Lys Ser Phe Asp Ala Tyr Tyr Cys Ser Gly 20 25 30 Ala Cys Gin Phe Pro Met Pro Lys Ser Leu Lys Pro Ser Asn His Ala 35 40 45 Thr Ile Gin Ser Ile Val Ala Arg Ala Val Gly Val Val Pro Gly Ile O P 7 - 78 - 50 55 60 Pro Glu Pro Cys Cys Val Pro Glu Lys Met Ser Ser Leu Ser Ile Leu 65 70 75 80 Phe Phe Asp Glu Asn Lys Asn Val Val Leu Lys Val Tyr Pro Asn Met 85 90 95 Thr Val Glu Ser Cys Ala Cys Arg 100 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: HOMO SAPIENS (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..102 (D) OTHER INFORMATION: /note- "BMP5" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gin 1 5 10 15 Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Phe Tyr Cys Asp Gly 20 25 30 Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala 35 40 45 Ile Val Gin Thr Leu Val His Leu Met Phe Pro Asp His Val Pro Lys 50 55 60 Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe 65 70 75 80 Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val 85 90 95 Arg Ser Cys Gly Cys His 100 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: HOMO SAPIENS (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..102 (D) OTHER INFORMATION: /note= "BMP6" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Cys Arg Lys His Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Gin 1 5 10 15 Asp Trp Ile Ile Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly 20 25 30 Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala 35 40 45 Ile Val Gin Thr Leu Val His Leu Met Asn Pro Glu Tyr Val Pro Lys 50 55 60 Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe 65 70 75 80 Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg Trp Met Val Val 85 90 95 Arg Ala Cys Gly Cys His 100 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1247 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: HOMO SAPIENS (F) TISSUE TYPE: BRAIN (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 84..1199 (D) OTHER INFORMATION: /product- "GDF-1" /note- "GDF-1 CDNA" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: GGGGACACCG GCCCCGCCCT CAGCCCACTG GTCCCGGGCC GCCGCGGACC CTGCGCACTC 60 TCTGGTCATC GCCTGGGAGG AAG ATG CCA CCG CCG CAG CAA GGT CCC TGC 110 Met Pro Pro Pro Gin Gin Gly Pro Cys 1 5 GGC CAC CAC CTC CTC CTC CTC CTG GCC CTG CTG CTG CCC TCG CTG CCC 158 Gly His His Leu Leu Leu Leu Leu Ala Leu Leu Leu Pro Ser Leu Pro 10 15 20 25 CTG ACC CGC GCC CCC GTG CCC CCA GGC CCA GCC GCC GCC CTG CTC CAG 206 Leu Thr Arg Ala Pro Val Pro Pro Gly Pro Ala Ala Ala Leu Leu Gin 30 35 40 GCT CTA GGA CTG CGC GAT GAG CCC CAG GGT GCC CCC AGG CTC CGG CCG 254 Ala Leu Gly Leu Arg Asp Glu Pro Gin Gly Ala Pro Arg Leu Arg Pro 45 50 55 GTT CCC CCG GTC ATG TGG CGC CTG TTT CGA CGC CGG GAC CCC CAG GAG 302 Val Pro Pro Val Met Trp Arg Leu Phe Arg Arg Arg Asp Pro Gin Glu 60 65 70 ACC AGG TCT GGC TCG CGG CGG ACG TCC CCA GGG GTC ACC CTG CAA CCG 350 Thr Arg Ser Gly Ser Arg Arg Thr Ser Pro Gly Val Thr Leu Gin Pro 75 80 85 TGC CAC GTG GAG GAG CTG GGG GTC GCC GGA AAC ATC GTG CGC CAC ATC 398 Cys His Val Glu Glu Leu Gly Val Ala Gly Asn Ile Val Arg His Ile 90 95 100 105 CCG GAC CGC GGT GCG CCC ACC CGG GCC TCG GAG CCT GTC TCG GCC GCG 446 Pro Asp Arg Gly Ala Pro Thr Arg Ala Ser Glu Pro Val Ser Ala Ala 110 115 120 GGG CAT TGC CCT GAG TGG ACA GTC GTC TTC GAC CTG TCG GCT GTG GAA 494 Gly His Cys Pro Glu Trp Thr Val Val Phe Asp Leu Ser Ala Val Glu 125 130 135 CCC GCT GAG CGC CCG AGC CGG GCC CGC CTG GAG CTG CGT TTC GCG GCG 542 Pro Ala Glu Arg Pro Ser Arg Ala Arg Leu Glu Leu Arg Phe Ala Ala 140 145 150 GCG GCG GCG GCA GCC CCG GAG GGC GGC TGG GAG CTG AGC GTG GCG CAA 590 Ala Ala Ala Ala Ala Pro Glu Gly Gly Trp Glu Leu Ser Val Ala Gin 155 160 165 GCG GGC CAG GGC GCG GGC GCG GAC CCC GGG CCG GTG CTG CTC CGC CAG 638 Ala Gly Gin Gly Ala Gly Ala Asp Pro Gly Pro Val Leu Leu Arg Gin 170 175 180 185 TTG GTG CCC GCC CTG GGG CCG CCA GTG CGC GCG GAG CTG CTG GGC GCC 686 Leu Val Pro Ala Leu Gly Pro Pro Val Arg Ala Glu Leu Leu Gly Ala 190 195 200 W - 81 - GCT TGG GCT CGC AAC GCC TCA TGG CCG CGC AGC CTC CGC CTG GCG CTG 734 Ala Trp Ala Arg Asn Ala Ser Trp Pro Arg Ser Leu Arg Leu Ala Leu 205 210 215 GCG CTA CGC CCC CGG GCC CCT GCC GCC TGC GCG CGC CTG GCC GAG GCC 782 Ala Leu Arg Pro Arg Ala Pro Ala Ala Cys Ala Arg Leu Ala Glu Ala 220 225 230 TCG CTG CTG CTG GTG ACC CTC GAC CCG CGC CTG TGC CAC CCC CTG GCC 830 Ser Leu Leu Leu Val Thr Leu Asp Pro Arg Leu Cys His Pro Leu Ala 235 240 245 CGG CCG CGG CGC GAC GCC GAA CCC GTG TTG GGC GGC GGC CCC GGG GGC 878 Arg Pro Arg Arg Asp Ala Glu Pro Val Leu Gly Gly Gly Pro Gly Gly 250 255 260 265 GCT TGT CGC GCG CGG CGG CTG TAC GTG AGC TTC CGC GAG GTG GGC TGG 926 Ala Cys Arg Ala Arg Arg Leu Tyr Val Ser Phe Arg Glu Val Gly Trp 270 275 280 CAC CGC TGG GTC ATC GCG CCG CGC GGC TTC CTG GCC AAC TAC TGC CAG 974 His Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn Tyr Cys Gin 285 290 295 GGT CAG TGC GCG CTG CCC GTC GCG CTG TCG GGG TCC GGG GGG CCG CCG 1022 Gly Gin Cys Ala Leu Pro Val Ala Leu Ser Gly Ser Gly Gly Pro Pro 300 305 310 GCG CTC AAC CAC GCT GTG CTG CGC GCG CTC ATG CAC GCG GCC GCC CCG 1070 Ala Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala Ala Ala Pro 315 320 325 GGA GCC GCC GAC CTG CCC TGC TGC GTG CCC GCG CGC CTG TCG CCC ATC 1118 Gly Ala Ala Asp Leu Pro Cys Cys Val Pro Ala Arg Leu Ser Pro Ile 330 335 340 345 TCC GTG CTC TTC TTT GAC AAC AGC GAC AAC GTG GTG CTG CGG CAG TAT 1166 Ser Val Leu Phe Phe Asp Asn Ser Asp Asn Val Val Leu Arg Gin Tyr 350 355 360 GAG GAC ATG GTG GTG GAC GAG TGC GGC TGC CGC TAACCCGGGG CGGGCAGGGA 1219 Glu Asp Met Val Val Asp Glu Cys Gly Cys Arg 365 370 CCCGGGCCCA ACAATAAATG CCGCGTGG 1247 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Met Pro Pro Pro Gin Gin Gly Pro Cys Gly His His Leu Leu Leu Leu 1 5 10 15 Leu Ala Leu Leu Leu Pro Ser Leu Pro Leu Thr Arg Ala Pro Val Pro 20 25 30 Pro Gly Pro Ala Ala Ala Leu Leu Gin Ala Leu Gly Leu Arg Asp Glu 35 40 45 Pro Gin Gly Ala Pro Arg Leu Arg Pro Val Pro Pro Val Met Trp Arg 50 55 60 Leu Phe Arg Arg Arg Asp Pro Gin Glu Thr Arg Ser Gly Ser Arg Arg 65 70 75 80 Thr Ser Pro Gly Val Thr Leu Gin Pro Cys His Val Glu Glu Leu Gly 85 90 95 Val Ala Gly Asn Ile Val Arg His Ile Pro Asp Arg Gly Ala Pro Thr 100 105 110 Arg Ala Ser Glu Pro Val Ser Ala Ala Gly His Cys Pro Glu Trp Thr 115 120 125 Val Val Phe Asp Leu Ser Ala Val Glu Pro Ala Glu Arg Pro Ser Arg 130 135 140 Ala Arg Leu Glu Leu Arg Phe Ala Ala Ala Ala Ala Ala Ala Pro Glu 145 150 155 160 Gly Gly Trp Glu Leu Ser Val Ala Gin Ala Gly Gin Gly Ala Gly Ala 165 170 175 Asp Pro Gly Pro Val Leu Leu Arg Gin Leu Val Pro Ala Leu Gly Pro 180 185 190 Pro Val Arg Ala Glu Leu Leu Gly Ala Ala Trp Ala Arg Asn Ala Ser 195 200 205 Trp Pro Arg Ser Leu Arg Leu Ala Leu Ala Leu Arg Pro Arg Ala Pro 210 215 220 Ala Ala Cys Ala Arg Leu Ala Glu Ala Ser Leu Leu Leu Val Thr Leu 225 230 235 240 Asp Pro Arg Leu Cys His Pro Leu Ala Arg Pro Arg Arg Asp Ala Glu 245 250 255 Pro Val Leu Gly Gly Gly Pro Gly Gly Ala Cys Arg Ala Arg Arg Leu 260 265 270 Tyr Val Ser Phe Arg Glu Val Gly Trp His Arg Trp Val Ile Ala Pro 275 280 285 Arg Gly Phe Leu Ala Asn Tyr Cys Gin Gly Gin Cys Ala Leu Pro Val 290 295 300 Ala Leu Ser Gly Ser Gly Gly Pro Pro Ala Leu Asn His Ala Val Leu 305 310 315 320 Arg Ala Leu Met His Ala Ala Ala Pro Gly Ala Ala Asp Leu Pro Cys 325 330 335 Cys Val Pro Ala Arg Leu Ser Pro Ile Ser Val Leu Phe Phe Asp Asn 340 345 350 Ser Asp Asn Val Val Leu Arg Gin Tyr Glu Asp Met Val Val Asp Glu 355 360 365 Cys Gly Cys Arg 370

Claims: CLAΓMS What is claimed is: 1. A method of treatment for a mammal in, or at risk of, chronic renal failure comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent or morphogen. 2. A method of treatment for a mammal in, or at risk of, chronic renal failure comprising administering to said mammal a therapeutically effective amount of an inducer of endogenous OP/BMP renal therapeutic agent or morphogen expression. 3. A method of treatment for a mammal in, or at risk of, chronic renal failure comprising administering to said mammal a therapeutically effective amount of an agonist of an OP/BMP renal therapeutic agent or morphogen receptor. 4. A method of treatment for a mammal in, or at risk of, chronic renal failure comprising introducing within the kidney of said mammal a therapeutically effective amount of renal mesenchymal progenitor cells. 5. A method as in claim 4 comprising the additional step of inducing metanephric differentiation of said cells by contacting said cells with an OP/BMP renal therapeutic agent or morphogen. 6. A method as in claim 4 comprising the additional step of inducing metanephric differentiation of said cells by contacting said cells with an inducer of an OP/BMP renal therapeutic agent or morphogen. 7. A method as in claim 4 comprising the additional step of inducing metanephric differentiation of said cells by contacting said cells with an agonist of an OP/BMP renal therapeutic agent or morphogen receptor. 8. A method of treatment to delay the need for, or reduce the frequency of, chronic dialysis treatments comprising administering to a mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent or morphogen. 9. A method of treatment to delay the need for, or reduce the frequency of, chronic dialysis treatments comprising administering to said mammal a therapeutically effective amount of an inducer of endogenous OP/BMP renal therapeutic agent or morphogen expression. 10. A method of treatment to delay the need for, or reduce the frequency of, chronic dialysis treatments comprising administering to said mammal a therapeutically effective amount of an agonist of an OP/BMP renal therapeutic agent or morphogen receptor. 11. A method as in any one of claims 1-10 wherein said mammal is afflicted with a condition selected from the group consisting of chronic renal failure, end-stage renal disease, chronic diabetic nephropathy, diabetic glomerulopathy, diabetic renal hypertrophy, hypertensive nephrosclerosis, hypertensive glomerulosclerosis, chronic glomerulonephritis, hereditary nephritis, and renal dysplasia. 12. A method as in any one of claims 1-10 wherein examination of a renal biopsy of said mammal indicates that said mammal is afflicted with a condition selected from the group consisting of glomerular hypertrophy, tubular hypertrophy, glomerulosclerosis, and tubulointerstitial sclerosis. 13. A method as in any one of claims 1-10 wherein examination of said mammal indicates renal fibrosis. 14. A method as in claim 13 wherein said examination is an ultrasound, MRI or CAT scan of said mammal. 15. A method as in any one of claims 1-10 wherein said mammal possesses a number of functional nephron units which is less than about 50% of a number of functional nephron units present in a mammal having intact healthy kidneys. 16. A method as in any one of claims 1-10 wherein said mammal possesses a number of functional nephron units which is less than about 40% of a number of functional nephron units present in a mammal having intact healthy kidneys. 17. A method as in any one of claims 1-10 wherein said mammal possesses a number of functional nephron units which is less than about 30% of a number of functional nephron units present in a mammal having intact healthy kidneys. 18. A method as in any one of claims 1-10 wherein said mammal possesses a number of functional nephron units which is less than about 20% of a number of functional nephron units present in a mammal having intact healthy kidneys. 19. A method as in any one of claims 1-10 wherein said mammal is a kidney transplant recipient. 20. A method as in any one of claims 1-10 wherein said mammal possesses only one kidney. 21. A method as in any one of claims 1-10 wherein examination of a urinary sediment of said mammal indicates a presence of broad casts. 22. A method as in any one of claims 1-10 wherein said mammal has a GFR which is chronically less than about 50% of a GFR cXp for said mammal. 23. A method as in claim 22 wherein said mammal has a GFR which is chronically less than about 40%> of a GFR eXp for said mammal. 24. A method as in claim 22 wherein said mammal has a GFR which is chronically less than about 30% of a GFRc Xp for said mammal. 25. A method as in claim 22 wherein said mammal has a GFR which is chronically less than about 20% of a GFR«φ for said mammal. 26. A method as in any one of claims 1-10 wherein said mammal is a human male weighing at least about 50 kg and has a GFR which is chronically less than about 50 ml/min. 27. A method as in claim 26 wherein said mammal is a human male weighing at least about 50 kg and has a GFR which is chronically less than about 40 ml/min. 28. A method as in claim 26 wherein said mammal is a human male weighing at least about 50 kg and has a GFR which is chronically less than about 30 ml/min. g7 29. A method as in claim 26 wherein said mammal is a human male weighing at least about 50 kg and has a GFR which is chronically less than about 20 ml/min. 30. A method as in any one of claims 1-10 wherein said mammal is a human female weighing at least about 40 kg and has a GFR which is chronically less than about 40 ml/min. 31. A method as in claim 30 wherein said mammal is a human female weighing at least about 40 kg and has a GFR which is chronically less than about 30 ml/min. 32. A method as in claim 30 wherein said mammal is a human female weighing at least about 40 kg and has a GFR which is chronically less than about 20 ml/min. 33. A method as in claim 30 wherein said mammal is a human female weighing at least about 40 kg and has a GFR which is chronically less than about 10 ml/min. 34. A method as in any one of claims 1-10 wherein said treatment reduces serum creatinine levels in said mammal by at least about 5% over 3 months. 35. A method as in any one of claims 1-10 wherein prior to said treatment said mammal presented a chronic decline in a clinical indicator of renal function; and after at least about 3 months of said treatment, said indicator stabilizes. 36. A method as in any one of claims 1-3 wherein said administration is oral. 37. A method as in any one of claims 1-3 wherein said administration is parenteral. 38. A method as in claim 37 wherein said administration is intravenous. 39. A method as in claim 37 wherein said administration is intraperitoneal. 40. A method as in claim 37 wherein said administration is into the renal capsule. 41. A method as in claim 37 wherein a stent has been implanted into said mammal for said administration. 42. A method as in claim 41 wherein said stent is an intravenous stent. 43. A method as in claim 41 wherein said stent is an intraperitoneal stent. 44. A method as in claim 41 wherein said stent is a renal intracapsular stent. 45. A method as in claim 37 wherein said administration is by an implanted device. 46. A method as in any one of claims 1-3 wherein said administration is at least once a week for a period of at least about one month. 47. A method as in any one of claims 1-3 wherein said administration is at least once a month for a period of at least about one year. 48. A method as in claim 1 wherein said OP/BMP renal therapeutic agent or morphogen is administered at a dosage of about 0.01-1000 μg/kg body weight of said mammal. 49. A method as in claim 48 wherein said OP/BMP renal therapeutic agent or moφhogen is administered at a dosage of about 10-300 μg/kg body weight of said mammal. 50. A method of promoting metanephric differentiation of renal mesenchymal progenitor cells comprising the step of contacting said cells with an OP/BMP renal therapeutic agent or morphogen in an amount effective to induce said differentiation. 51. A method as in claim 1 wherein said renal therapeutic agent comprises a polypeptide consisting of at least a C-terminal cysteine domain of a protein selected from the group consisting of a pro form, a mature form, and a soluble form of a polypeptide selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, and BMP9. 52. A method as in claim 51 wherein said renal therapeutic agent comprises a polypeptide consisting of at least a C-terminal cysteine domain of a protein selected from the group consisting of a pro form, a mature form, and a soluble form of human OP-1. 53. A method as in claim 1 wherein said renal therapeutic agent comprises a polypeptide having at least 70%> homology with an amino acid sequence of a C-terminal seven-cysteine domain of human OP- 1. 54. A method as in claim 53 wherein said polypeptide has at least 75% homology with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1. 55. A method as in claim 53 wherein said polypeptide has at least 80%> homology with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1. 56. A method as in claim 53 wherein said polypeptide has at least 60% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP- 1.

Inventors: COHEN CHARLES M, SAMPATH KUBER T, COHEN, CHARLES, M., SAMPATH, KUBER, T.
Applicants: CREATIVE BIOMOLECULES INC, CREATIVE BIOMOLECULES, INC.
Application year: 1997
Main classification: A61K38
IPC codes: A61K31, A61K38, A61K45, A61P3, A61P9, A61P13, C07K14